Methods for treatment of refractory generalized myasthenia gravis
Eculizumab effectively targets complement activation to improve neuromuscular function and reduce autoimmune damage in refractory gMG, offering significant clinical improvements and potentially reducing the need for ongoing immunosuppressive treatments.
Patent Information
- Application Number
- JP2024134758
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-05-03
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for refractory generalized myasthenia gravis (gMG) do not specifically target the underlying pathology of neuromuscular junction (NMJ) injury, leading to inadequate response in some patients despite immunosuppressive therapy, and there is a need for alternative treatments to manage chronic symptoms and improve neuromuscular function.
Administration of a therapeutically effective amount of an anti-complement component 5 (C5) antibody, such as eculizumab, to inhibit complement activation and inflammation at the NMJ, thereby reducing autoimmune damage and improving neuromuscular function.
Eculizumab treatment results in clinically significant improvements in myasthenia gravis activities of daily living (MG-ADL), quantitative myasthenia gravis score (QMG), Myasthenia Gravis Composite (MGC), quality of life, and neuro-fatigue, with some patients experiencing reductions in immunosuppressive therapy requirements.
Smart Images

Figure 2024156984000034 
Figure 2024156984000035 
Figure 2024156984000036
Abstract
Description
[Technical field]
[0001] background Myasthenia gravis (MG) is a rare, debilitating, acquired autoimmune neuropathy of the neuromuscular junction (NMJ) caused by dysfunction of neuromuscular transmission resulting from autoantibody (Ab) binding to proteins involved in signal transduction at the NMJ, including the nicotinic acetylcholine receptor (AChR) or, less frequently, the muscle-specific tyrosine kinase (MuSK) involved in AChR clustering. [Background technology]
[0002] MG has a prevalence of 14-20 per 100,000 in the United States, affecting approximately 60,000 Americans. It affects men and women in equal proportions, but incidence in women peaks in the 30s compared with men, who have a peak age of onset in their 60s or 70s. Mortality from MG is approximately 4%, with most cases due to respiratory failure.
[0003] Myasthenia gravis is clinically characterized by weakness and fatigability of voluntary skeletal muscles. MG may initially present with ocular muscle weakness, termed ocular MG (oMG), which may affect eye and eyelid movement. Ten percent of subjects have disease limited to the eye muscles. Ninety percent of subjects have generalized MG with muscle weakness involving the neck, head, spine, bulbar, respiratory, or limb muscles. Bulbar weakness refers to muscles controlled by nerves originating from the bulb-like part of the brain stem and manifests as difficulty speaking, chewing, swallowing, and head control. MG can cause life-threatening respiratory failure, termed myasthenic crisis. Approximately 15%-20% of subjects experience a myasthenic crisis during the course of their disease, 75% within 2 years of diagnosis, requiring hospitalization and ventilatory support. Summary of the Invention [Problem to be solved by the invention]
[0004] Although there is no cure for MG, there are various treatments that reduce muscle weakness and improve neuromuscular function. Currently available treatments for myasthenia gravis aim to modulate neuromuscular transmission, inhibit the production or effects of pathogenic antibodies, or inhibit inflammatory cytokines. There are currently no specific treatments that specifically target the pathology underlying NMJ injury. Anti-AChR antibody-AChR interactions result in complement activation and inflammation via the classical pathway, resulting in destruction of the NMJ. There are no specific treatments that correct the autoimmune defect in MG. With immunosuppressive therapy (IST), the current standard of care usually combines cholinesterase inhibitors, corticosteroids, and immunosuppressants (most commonly azathioprine [AZA], cyclosporine, and mycophenolate mofetil [MMF]), and the majority of subjects with MG have their disease fairly well controlled. However, there exists a cohort of refractory subjects who do not respond adequately to or are intolerant to IST and require plasma exchange (PE) and / or intravenous immunoglobulin (IVIg) to maintain clinical stability. Alternative therapies are needed for these subjects. [Means for solving the problem]
[0005] Abstract The present disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an anti-complement component 5 (C5) antibody or antigen-binding fragment thereof, wherein the patient is at least Both are administered for 26 weeks.
[0006] In certain embodiments, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an anti-C5 antibody, or antigen-binding fragment thereof, wherein the anti-C5 antibody, or antigen-binding fragment thereof, is eculizumab or an eculizumab variant, and the patient is administered eculizumab or an eculizumab variant for at least 26 weeks.
[0007] In another embodiment, the disclosure provides a method comprising administering a therapeutically effective amount of eculizumab to a patient, where the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR) and shows marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST), and requires chronic plasma exchange or chronic IVIg to maintain clinical stability; and where the patient is administered eculizumab for at least 26 weeks.
[0008] In one embodiment, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient, wherein the patient tests positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR) and shows marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST) and has previously failed treatment with at least two immunosuppressants, or has failed treatment with at least one immunosuppressant and has received chronic plasma exchange or IVIg, and has an MG-ADL total score > 6 at study enrollment; wherein eculizumab and wherein the patient has received eculizumab for at least 26 weeks; the 28 day induction phase of eculizumab treatment is followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose and 1200 mg of eculizumab every 14 ± 2 days thereafter, and wherein the patient has a clinically meaningful improvement (reduction) in two measures of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, and MGC.
[0009] In certain embodiments, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient, wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR) and shows marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST), or requires chronic plasma exchange or chronic IVIg to maintain clinical stability; wherein eculizumab is administered using a phased dosing schedule comprising an induction phase comprising administering a 900 mg induction dose of eculizumab on day 1, administering 900 mg doses of eculizumab on days 7, 14, and 21, and administering 1200 mg of eculizumab as a fifth induction dose on day 28, wherein the patient is administered eculizumab for at least 26 weeks.
[0010] In a further embodiment, the disclosure provides a method wherein a 28 day induction phase of eculizumab treatment is followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose, and 1200 mg of eculizumab every 14±2 days thereafter.
[0011] In certain embodiments, the present disclosure provides a method for administering a therapeutically effective amount of a medicament for a patient, the method comprising administering to said patient ... The present invention provides a method of administering eculizumab to a patient at a dose between 300 mg and 1200 mg within 4 hours of completing the plasmapheresis, wherein the third phase further comprises administering eculizumab to the patient at a dose between 600 mg and 900 mg within 90 minutes of completing the plasmapheresis. In yet another embodiment, the third phase comprises administering eculizumab to the patient at a dose between 600 mg and 900 mg within 1 hour of completing the plasmapheresis.
[0012] In one embodiment, the patient treated by the method provided herein experiences clinically significant improvement (reduction) in myasthenia gravis activities of daily living (MG-ADL) score after 26 weeks of treatment.In certain embodiments, the clinically significant improvement that the patient experiences is at least 3 points reduction in the MG-ADL score of the patient after 26 weeks of treatment.In another embodiment, the clinically significant improvement that the patient experiences is 4 points reduction in the MG-ADL score of the patient after 26 weeks of treatment.
[0013] In another embodiment, the patient treated by the method provided herein experiences a clinically significant improvement (reduction) in quantitative myasthenia gravis score (QMG) after 26 weeks of treatment.In certain embodiments, the clinically significant improvement experienced by the patient is a reduction of at least 4 points in the patient's QMG score after 26 weeks of treatment.In another embodiment, the clinically significant improvement experienced by the patient is a reduction of 5 points in the patient's QMG score after 26 weeks of treatment.
[0014] In another embodiment, the patient treated by the method provided herein experiences a clinically significant improvement (reduction) in Myasthenia Gravis Composite (MGC) score after 26 weeks of treatment.In certain embodiments, the clinically significant improvement experienced by the patient is a reduction of at least 6 points in the patient's MGC score after 26 weeks of treatment.In another embodiment, the clinically significant improvement experienced by the patient is a reduction of at least 10 points in the patient's MGC score after 26 weeks of treatment.
[0015] In another embodiment, the patient treated by the method provided herein experiences a clinically meaningful improvement (reduction) in quality of life as measured by Myasthenia Gravis Quality of Life (MG-QOL-15) score after 26 weeks of treatment.In certain embodiments, the clinically meaningful improvement experienced by the patient is a reduction of at least 6 points in the patient's MG-QOL-15 score after 26 weeks of treatment.In another embodiment, the clinically meaningful improvement experienced by the patient is a reduction of at least 11 points in the patient's MG-QOL-15 score after 26 weeks of treatment.
[0016] In another embodiment, the patient treated by the method provided herein experiences a clinically significant improvement (reduction) in neuro-fatigue as measured by Neuro-QOL fatigue score after 26 weeks of treatment.In certain embodiments, the clinically significant improvement experienced by the patient is at least an 8-point reduction in the Neuro-QOL score of the patient after 26 weeks of treatment.In another embodiment, the clinically significant improvement experienced by the patient is at least a 16-point reduction in the Neuro-QOL score of the patient after 26 weeks of treatment.
[0017] In certain embodiments, patients treated by the methods provided herein experience a clinically meaningful improvement (increase) in health status as measured by EQ-5D health status score after 26 weeks of treatment.
[0018] In certain embodiments, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient, wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR) and exhibits marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability; wherein eculizumab is administered by administering a 900 mg induction dose of eculizumab on day 1, exacerbation on days 7, 14, and 21. and administering 1200 mg of eculizumab as a fifth dose on day 28, and a 900 mg dose of eculizumab as a fifth dose on day 28, wherein the patient is administered eculizumab for at least 26 weeks; wherein a 28 day induction phase of eculizumab treatment is followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose and administering 1200 mg of eculizumab every 14 ± 2 days thereafter, and the patient has a clinically meaningful improvement (reduction) in at least one measure of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL.
[0019] In another embodiment, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient, wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR) and shows marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability; wherein eculizumab is administered by administering a 900 mg induction dose of eculizumab on day 1, exacerbation on days 7, 14, and 21. and administering 1200 mg of eculizumab as a fifth dose on day 28, wherein the patient is administered eculizumab for at least 26 weeks; and wherein a 28 day induction phase of eculizumab treatment is followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose and administering 1200 mg of eculizumab every 14±2 days thereafter, and the patient has a clinically meaningful improvement (reduction) in two measures of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL.
[0020] In another embodiment, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient, wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR) and shows marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST), or requires chronic plasma exchange or chronic IVIg to maintain clinical stability; wherein eculizumab is administered by administering a 900 mg induction dose on day 1, eculizumab on days 7, 14, and 21. The patient is administered eculizumab using a phased dosing schedule comprising administering a 900 mg dose of eculizumab and administering 1200 mg as a fifth dose on day 28, wherein the patient is administered eculizumab for at least 26 weeks; wherein the 28-day induction phase of eculizumab treatment is followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose and administering 1200 mg of eculizumab every 14±2 days thereafter, and the patient has a clinically meaningful improvement (reduction) in three measures of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL. In certain embodiments, the patient has a clinically meaningful improvement (reduction) in four measures of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL. In another embodiment, the patient has clinically significant improvement in five measures of generalized myasthenia gravis severity. There was a significant improvement (reduction) in the five measures of generalized myasthenia gravis severity: MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL.
[0021] In another embodiment, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient, wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR) and shows marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST), or requires chronic plasma exchange or chronic IVIg to maintain clinical stability; wherein eculizumab is administered by administering a 900 mg induction dose on day 1, 900 mg doses of eculizumab on days 7, 14, and 21, and 1200 mg as a fifth dose on day 28. wherein the patient is administered eculizumab for at least 26 weeks; wherein a 28 day induction phase of eculizumab treatment is followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose and 1200 mg every 14±2 days thereafter, and the patient has a clinically meaningful improvement (reduction) in five measures of generalized myasthenia gravis severity, wherein the five measures of generalized myasthenia gravis severity are a reduction of at least 3 points in MG-ADL, a reduction of at least 4 points in QMG, a reduction of at least 6 points in MGC, a reduction of at least 6 points in MG-QOL, and a reduction of at least 8 points in Neuro-QOL. In certain embodiments, the patient has a clinically meaningful improvement (reduction) in five measures of generalized myasthenia gravis severity, where the five measures of generalized myasthenia gravis severity are a reduction of at least 4 points in MG-ADL, a reduction of at least 5 points in QMG, a reduction of at least 10 points in MGC, a reduction of at least 11 points in MG-QOL, and a reduction of at least 16 points in Neuro-QOL.
[0022] In a further embodiment, the present disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof, comprising administering eculizumab by intravenous infusion. In another embodiment, eculizumab is administered subcutaneously. In another embodiment, eculizumab comprises a heavy chain amino acid sequence according to SEQ ID NO: 10 and a light chain amino acid sequence according to SEQ ID NO: 11. In yet another embodiment, eculizumab is an eculizumab variant comprising a heavy chain amino acid sequence according to SEQ ID NO: 14 and a light chain amino acid sequence according to SEQ ID NO: 11. In a particular embodiment, eculizumab is an eculizumab variant comprising a heavy chain variable region amino acid sequence according to SEQ ID NO: 12 and a light chain amino acid sequence according to SEQ ID NO: 11.
[0023] In yet another embodiment, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering an anti-C5 antibody, or an antigen-binding fragment thereof, wherein the antibody is an anti-C5 antibody or an antigen-binding fragment thereof comprising a heavy chain variable region amino acid sequence according to SEQ ID NO: 27 and a light chain variable region amino acid sequence according to SEQ ID NO: 28. In yet another embodiment, the antibody is an anti-C5 antibody or an antigen-binding fragment thereof comprising a heavy chain variable region amino acid sequence according to SEQ ID NO: 35 and a light chain variable region amino acid sequence according to SEQ ID NO: 36. In yet another embodiment, the antibody is an anti-C5 antibody or an antigen-binding fragment thereof comprising a heavy chain variable region amino acid sequence according to SEQ ID NO: 37 and a light chain variable region amino acid sequence according to SEQ ID NO: 38.
[0024] In one embodiment, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering an anti-C5 antibody or antigen-binding fragment thereof, wherein the patient has failed treatment with two or more ISTs, either sequentially or in combination, for one or more years.
[0025] In one embodiment, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering an anti-C5 antibody or antigen-binding fragment thereof, wherein the patient has failed at least one IST and requires chronic plasma exchange or IVIg to control symptoms of myasthenia gravis.
[0026] In one embodiment, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering a therapeutically effective amount of eculizumab, wherein the therapeutically effective amount of eculizumab is maintained at a concentration of between 50-100 μg / mL in the patient's serum.
[0027] In one embodiment, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering a therapeutically effective amount of eculizumab, wherein the patient experiences cessation of administration of one or more ISTs after at least 26 weeks of treatment.
[0028] In one embodiment, the disclosure provides a method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering a therapeutically effective amount of eculizumab, wherein the patient experiences a reduction in IST dosing after at least 26 weeks of treatment. [Brief description of the drawings]
[0029] [Figure 1] FIG. 1 is a diagram of the overall design of the clinical trial disclosed herein. [Figure 2A] FIG. 2A is a diagram of the EUROQOL (EQ-5D) survey of health status questionnaire used in the clinical trial disclosed herein. [Figure 2B] FIG. 2B is a diagram of the EUROQOL (EQ-5D) survey of health status questionnaire used in the clinical trial disclosed herein. [Diagram 3] FIG. 3 is a diagram of the N. meningitidis vaccination schedule used in the clinical trials disclosed herein. [Figure 4] FIG. 4 is a diagram of the dosing schedule used in the clinical trials disclosed herein. [Diagram 5] FIG. 5 is a diagram of the dosing, clinical evaluation and safety follow-up schedule used in the clinical trials disclosed herein. [Figure 6] FIG. 6 is a diagram of the dosing schedule used in the clinical trial, including the extension period, disclosed herein. [Figure 7] FIG. 7 is a graphical depiction of the changes from baseline in MG-ADL values obtained for the placebo and eculizumab groups during the initial 26 weeks of the study. [Figure 8] FIG. 8 is a graphical representation of the changes from baseline in QMG values obtained for the placebo and eculizumab groups during the initial 26 weeks of the study. [Figure 9] FIG. 9 is a graphical representation of the changes from baseline in MGC values obtained for the placebo and eculizumab groups during the initial 26 weeks of the study. [Figure 10] FIG. 10 is a graphical representation of the change from baseline in MG-QOL 15 scores obtained for the placebo and eculizumab groups during the initial 26 weeks of the study. [Figure 11] FIG. 11 is a graphical representation of the number of patients in both the placebo and eculizumab treatment groups who achieved between 5 and 10 points in QMG score during the initial 26 weeks of the study. [Figure 12] FIG. 12 is a diagram of the REGAIN study design. [Figure 13] FIG. 13 is a graphical representation of the responder analysis (MG-ADL and QMG) showing the proportion of patients with improvement in total score and no rescue therapy from baseline to week 26. [Figure 14] FIG. 14 is a graphical depiction of the proportion of patients with a ≧3, ≧5, or ≧8 point decrease in MG-ADL total score and no rescue therapy over the period from baseline to 26 weeks. [Figure 15]FIG. 15 is a graphical depiction of the proportion of patients with a ≧5, ≧7, or ≧10 point decrease in QMG total score and no rescue from baseline to week 26. [Figure 16] FIG. 16 is a graphical representation of dual responders (assessed by MG-ADL and QMG total scores) with no rescue therapy at 26 weeks. [Figure 17] FIG. 17 is a graphical depiction of the proportion of patients with at least a 3-point improvement in MG-ADL total score and a ≧5-point improvement in QMG total score and no rescue therapy assessed over time from baseline to week 26. [Figure 18] Figure 18 is a graphical representation of the percentage of patients simultaneously meeting increasingly stringent criteria based on MG-ADL and QMG. The bottom row shows the thresholds for both scales above the MCID (minimal clinically significant difference: 3 for MG-ADL and 5 for QMG). Higher bars represent increasing thresholds. The rightmost panel shows the odds ratios for meeting each threshold for eculizumab-treated patients versus placebo-treated patients. [Figure 19] FIG. 19 is a graphical representation of the change from baseline in MG-ADL total score (LS mean and 95% CI) by treatment arm over time from ECU-MG-302 baseline to week 52 in Study ECU-MG-302 using a repeated measures model. [Figure 20] FIG. 20 is a graphical depiction of the change from baseline in MG-ADL total score (mean and 95% CI) by treatment arm over time from ECU-MG-301 baseline to week 52 in Study ECU-MG-302. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] Detailed Description The present disclosure provides a method of treating myasthenia gravis (MG) in a subject or patient in need thereof by administering an antibody that specifically binds to complement component 5 (C5). In certain embodiments, the antibody that specifically binds to C5 reduces the rate at which C5 is cleaved in vivo into C5a and C5b. In other embodiments, the antibody that specifically binds to C5 binds to one or both of the C5a and / or C5b fragments. In any of these embodiments, the antibody that specifically binds to C5 blocks the complement cascade at C5, thereby reducing the release of proinflammatory mediators such as C5a and the formation of the C5b-9 membrane attack complex (MAC).
[0031] In certain embodiments, the antibody that specifically binds to C5 is eculizumab. In more particular embodiments, eculizumab is an antibody or a fragment thereof.
[0032] Eculizumab (h5G1.1-mAb) is a humanized monoclonal antibody (mAb) derived from the murine anti-human C5 antibody m5G1.1. Eculizumab specifically binds to the terminal complement protein C5, thereby inhibiting its cleavage into C5a and C5b during complement activation. This strategic blockade of the complement cascade at C5 prevents the release of proinflammatory mediators and the formation of the membrane attack complex or cytolytic pores, while preserving the early components of complement activation that are essential for opsonization of microorganisms and clearance of immune complexes.
[0033] C5 binding protein is described in U.S. Patent No. 6,355,245 (herein incorporated by reference in its entirety).In certain embodiments, anti-C5 antibody is a monoclonal antibody with hybrid IgG2 / 4 isotype.In other embodiments, anti-C5 antibody is effective in reducing the cytolytic ability of complement present in human blood.This property of antibody can be determined by methods well known in the art, such as, for example, chicken erythrocyte hemolysis method described in U.S. Patent No. 6,355,245.
[0034] In certain embodiments, the anti-C5 antibody binds to C5 or a fragment thereof, such as C5a or C5b. In other embodiments, the anti-C5 antibody recognizes and binds to an epitope on either the alpha or beta chain of purified human complement component C5, and can block the conversion of C5 to C5a and C5b by C5 convertase. Wurzner et al., Complement. Inflamm. 8(5-6): See 328-40 (1991).
[0035] In another embodiment, the anti-C5 antibody recognizes and binds to an epitope within the alpha chain of purified human complement component C5. In this embodiment, the antibody is capable of blocking the conversion of C5 to C5a and C5b by C5 convertase. In one example of this embodiment, the antibody can effect this blocking at substantially the same concentrations as those required to block hemolytic activity.
[0036] In some embodiments, the antibodies specifically bind to the amino-terminal region in the alpha chain, but they do not specifically bind to free C5a. In certain embodiments, the C5 antibodies can substantially inhibit complement hemolytic activity and substantially inhibit the conversion of C5 to produce C5a. In some embodiments, the C5 antibodies perform these functions when used at a molar ratio of antibody to antigen (C5) of 3:1 or less.
[0037] The term "antibody" as used herein refers to immunoglobulins produced in vivo, as well as those produced in vitro by hybridomas, and antigen-binding fragments of such immunoglobulins (e.g., Fab' preparations), as well as recombinantly expressed antibodies or antigen-binding proteins, including immunoglobulins, chimeric immunoglobulins, "humanized" immunoglobulins, antigen-binding fragments of such immunoglobulins, single chain antibodies, and other recombinant proteins containing antigen-binding domains derived from immunoglobulins, such as DVD-Ig and CODV-Ig. See U.S. Patent Nos. 7,161,181 and 9,181,349. "Specificity" refers to the ability of a binding protein to selectively recognize and bind an antigen at a particular location or structure, known as an epitope, that is often found on the surface of the antigen.
[0038] The term "specifically binds" means that the binding protein or fragment thereof forms a complex with an antigen that is relatively stable under physiological conditions. Specific binding is at least about 1x10 -6 In another embodiment, the dissociation constant is at least about 1x10 -7 M, 1x10 -8 M, 1x10 -9 Medium, or 1x10 -10 M. Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like.
[0039] The anti-C5 antibodies described herein bind to complement component C5 (e.g., human C5) and inhibit cleavage of C5 into fragments C5a and C5b. Anti-C5 antibodies (or VH / VL domains derived therefrom) suitable for use in the present invention can be generated using methods known in the art.
[0040] An exemplary anti-C5 antibody is eculizumab, or antigen-binding fragments and variants thereof, comprising heavy and light chains having the sequences set forth in SEQ ID NOs: 10 and 11, respectively. Eculizumab (SOLIRIS (R) (also known as IL-16) is described in U.S. Patent No. 6,355,245. Eculizumab is a humanized monoclonal antibody that is a terminal complement inhibitor.
[0041] In other embodiments, the antibody comprises the heavy and light chain complementarity determining regions (CDRs) of eculizumab. ) or variable regions. Thus, in one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of eculizumab having the sequence set forth in SEQ ID NO:7, and the CDR1, CDR2, and CDR3 domains of the VL region of eculizumab having the sequence set forth in SEQ ID NO:8. In another embodiment, the antibody comprises heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs:1, 2, and 3, respectively, and light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs:4, 5, and 6, respectively. In another embodiment, the antibody comprises the VH and VL regions having the amino acid sequences set forth in SEQ ID NOs:7 and 8, respectively.
[0042] Empirical data show that serum eculizumab concentrations greater than 50 μg / mL and approaching at least 100 μg / mL are required to significantly reduce free C5 concentrations. In particular, free C5 concentrations significantly decreased as eculizumab concentrations increased starting at >50 μg / mL, and were near zero levels at eculizumab concentrations greater than 100 μg / ml. Thus, in various embodiments, the method comprises administering a therapeutically effective amount of eculizumab to a subject, wherein the therapeutically effective amount of eculizumab is maintained at a concentration of at least 50 μg / mL of eculizumab in the serum of the subject. In another embodiment, the method comprises administering a therapeutically effective amount of eculizumab to a subject, wherein the therapeutically effective amount of eculizumab is maintained at a concentration of at least 60 μg / mL of eculizumab in the serum of the subject. In one embodiment, the method comprises administering a therapeutically effective amount of eculizumab to the subject, wherein the therapeutically effective amount of eculizumab is maintained at a concentration of at least 70 μg / mL of eculizumab in the serum of the subject.In another embodiment, the method comprises administering a therapeutically effective amount of eculizumab to the subject, wherein the therapeutically effective amount of eculizumab is maintained at a concentration of at least 80 μg / mL of eculizumab in the serum of the subject.In another embodiment, the method comprises administering a therapeutically effective amount of eculizumab to the subject, wherein the therapeutically effective amount of eculizumab is maintained at a concentration of at least 90 μg / mL of eculizumab in the serum of the subject.In another embodiment, the method comprises administering a therapeutically effective amount of eculizumab to the subject, wherein the therapeutically effective amount of eculizumab is maintained at a concentration of at least 100 μg / mL of eculizumab in the serum of the subject.
[0043] Another exemplary anti-C5 antibody is an eculizumab variant known as BNJ441, an antibody engineered to have a longer half-life (T1 / 2) in humans, comprising heavy and light chains having the sequences set forth in SEQ ID NOs: 14 and 11, respectively, or antigen-binding fragments and variants thereof. BNJ441 (also known as ALXN1210) is described in International Publication No. WO 2015 / 134894 A1 and U.S. Patent No. 9,079,949, the teachings of which are incorporated herein by reference. BNJ441 is a novel variant of eculizumab (SOLIRIS (R) BNJ441 is a humanized monoclonal antibody structurally related to C5. BNJ441 selectively binds to the human complement protein C5 and inhibits its cleavage into C5a and C5b during complement activation. This inhibition prevents the release of the proinflammatory mediator C5a and the formation of the membrane attack complex C5b-9, which forms cytolytic pores, while preserving the proximal or early components of complement activation (e.g., C3 and C3b), which are essential for opsonization of microorganisms and clearance of immune complexes.
[0044] In other embodiments, the antibody comprises the heavy and light chain CDRs or variable regions of BNJ441. Thus, in one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of BNJ441 having the sequence set forth in SEQ ID NO: 12, and the CDR1, CDR2, and CDR3 domains of the VL region of BNJ441 having the sequence set forth in SEQ ID NO: 8. In another embodiment, the antibody comprises the heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NO: 19, 18, and 3, respectively, and the light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NO: 4, 5, and 6, respectively. In another embodiment, the antibody comprises the heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NO: 12 and SEQ ID NO: 8, respectively. In another embodiment, the antibody may comprise a heavy chain constant region of BNJ441 having the amino acid sequence set forth in SEQ ID NO:13.
[0045] In various embodiments, eculizumab is administered in a multi-phase dosing regimen. For example, the multi-phase dosing regimen includes a first phase and a second phase in various embodiments. In certain embodiments, the first phase is an induction phase and includes administering eculizumab between 900 mg once a week to the subject for 1-10 weeks. The induction phase is terminated by administering a first maintenance phase dose of 1200 mg one week after the last 900 mg dose.
[0046] In other embodiments, the second phase is a maintenance phase and includes administering between 1000 and 1400 mg of eculizumab once every two weeks to the subject for 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, 26 weeks, or as long as myasthenia gravis persists. In other embodiments, the maintenance phase includes administering between 1000 and 1400 mg of eculizumab once every two weeks to the subject for 2 months, 4 months, 6 months, 8 months, 12 months, 2 years, 3 years, 4 years, 5 years, or for the remaining life of the patient. In other embodiments, once the induction phase is complete, the maintenance phase includes administering eculizumab at about 1200 mg twice a month (every other week).
[0047] In another embodiment, the method comprises administering a therapeutically effective amount of eculizumab or an eculizumab variant to a subject, wherein the therapeutically effective amount of eculizumab or an eculizumab variant is maintained at a concentration of eculizumab in the serum of the subject between 50-100 μg / mL, between 60-100 μg / mL, between 70-100 μg / mL, between 80-100 μg / mL, or between 90-100 μg / mL.
[0048] Another exemplary anti-C5 antibody is the antibody BNJ421, comprising heavy and light chains having the sequences set forth in SEQ ID NOs: 20 and 11, respectively, or antigen-binding fragments and variants thereof. BNJ421 (also known as ALXN1211) is described in International Publication No. WO 2015 / 134894 A1 and U.S. Patent No. 9,079,949, the teachings of which are incorporated herein by reference.
[0049] In other embodiments, the antibody comprises the heavy and light chain CDRs or variable regions of BNJ421. Thus, in one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of BNJ421 having the sequence set forth in SEQ ID NO: 12, and the CDR1, CDR2, and CDR3 domains of the VL region of BNJ421 having the sequence set forth in SEQ ID NO: 8. In another embodiment, the antibody comprises the heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18, and 3, respectively, and the light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively. In another embodiment, the antibody comprises the VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO: 8, respectively. In another embodiment, the antibody may comprise the heavy chain constant region of BNJ421 having the amino acid sequence set forth in SEQ ID NO: 9.
[0050] Another exemplary anti-C5 antibody is the 7086 antibody described in U.S. Patent Nos. 8,241,628 and 8,883,158. In one embodiment, the antibody may comprise the heavy and light chain CDRs or variable regions of the 7086 antibody. See U.S. Patent Nos. 8,241,628 and 8,883,158. In another embodiment, the antibody or fragment thereof may comprise heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs:21, 22, and 23, respectively, and light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs:24, 25, and 26, respectively. In another embodiment, the antibody or fragment thereof may comprise the VH region of the 7086 antibody having the sequence set forth in SEQ ID NO:27, and the VL region of the 7086 antibody having the sequence set forth in SEQ ID NO:28. It can be seen.
[0051] Another exemplary anti-C5 antibody is the 8110 antibody, also described in U.S. Patent Nos. 8,241,628 and 8,883,158. In one embodiment, the antibody may comprise the heavy and light chain CDRs or variable regions of the 8110 antibody. The antibody or fragment thereof may comprise heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs:29, 30, and 31, respectively, and light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs:32, 33, and 34, respectively. In another embodiment, the antibody may comprise the VH region of the 8110 antibody having the sequence set forth in SEQ ID NO:35, and the VL region of the 8110 antibody having the sequence set forth in SEQ ID NO:36.
[0052] Another exemplary anti-C5 antibody comprises a heavy chain variable region amino acid sequence according to SEQ ID NO:37 and a light chain variable region amino acid sequence according to SEQ ID NO:38.
[0053] In various embodiments, eculizumab, eculizumab variants such as BNJ441, or other anti-C5 antibodies are administered to the subject once a month, once every two months, or once every three months, depending on the dose. In another embodiment, eculizumab, eculizumab variants such as BNJ441, or other anti-C5 antibodies are administered once every two weeks, once a week, twice a week, or three times a week. In other embodiments, eculizumab, eculizumab variants such as BNJ441, or other anti-C5 antibodies are administered once a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, or once every eight weeks, depending on the needs of the patient. In certain embodiments, eculizumab, eculizumab variants such as BNJ441, or other anti-C5 antibodies are administered intravenously (IV) or subcutaneously (SubQ).
[0054] Also provided herein is a pharmaceutical composition for the treatment of MG comprising an anti-C5 antibody or an antigen-binding fragment thereof together with a pharma- ceutically acceptable excipient. In one embodiment, the composition comprises an antibody comprising the CDR1, CDR2, and CDR3 domains of the VH region of eculizumab having the sequence set forth in SEQ ID NO:7, and the CDR1, CDR2, and CDR3 domains of the VL region of eculizumab having the sequence set forth in SEQ ID NO:8. In another embodiment, the antibody comprises heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs:1, 2, and 3, respectively, and light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs:4, 5, and 6, respectively. In another embodiment, the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NOs:7 and 8, respectively.
[0055] In some embodiments, the antibody comprises the heavy and light chain CDRs or variable regions of BNJ441. In one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of BNJ441 having the sequence set forth in SEQ ID NO: 12, and the CDR1, CDR2, and CDR3 domains of the VL region of BNJ441 having the sequence set forth in SEQ ID NO: 8. In another embodiment, the antibody comprises the heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18, and 3, respectively, and the light chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively. In another embodiment, the antibody comprises the VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO: 8, respectively.
[0056] In some embodiments, the antibody comprises the heavy and light chain CDRs or variable regions of BNJ421. In one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of BNJ421 having the sequence set forth in SEQ ID NO: 12, and the CDR1, CDR2, and CDR3 domains of the VL region of BNJ421 having the sequence set forth in SEQ ID NO: 8. In another embodiment, the antibody comprises heavy chain CDR1, CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18, and 3, respectively, and light chain CDR1CDR2, and CDR3 domains having the sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively, and the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO: 8, respectively.
[0057] 1. Methods of Treating Myasthenia Gravis The present disclosure provides a method of treating a subject suffering from myasthenia gravis (MG) by administering an antibody that specifically binds to C5. In other embodiments, the subject is a mammalian subject.
[0058] As used herein, the terms "subject" and "patient" are interchangeable. In certain embodiments, the subject and / or patient is a mammal. According to certain embodiments, primates include humans. Thus, in certain embodiments, the subject or patient suffering from MG described herein is a human.
[0059] In certain embodiments, MG includes refractory generalized myasthenia gravis. In some embodiments, refractory generalized myasthenia gravis is characterized as including subjects or patients who are positive for autoantibodies binding to nicotinic acetylcholine receptor (anti-AChR) and continue to show significant generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving current standard treatment for myasthenia gravis, such as cholinesterase inhibitor therapy and immunosuppressant therapy (IST), or require chronic plasma exchange or chronic IVIg to maintain clinical stability. In other embodiments, refractory generalized myasthenia gravis is characterized as including subjects or patients who continue to show significant generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving current standard treatment for myasthenia gravis, such as cholinesterase inhibitor therapy and immunosuppressant therapy (IST), or require chronic plasma exchange or chronic IVIg to maintain clinical stability.
[0060] In other embodiments, MG includes refractory generalized myasthenia gravis. In some embodiments, refractory generalized myasthenia gravis is characterized as including subjects or patients who are positive for autoantibodies binding to nicotinic acetylcholine receptor (anti-AChR) and who continue to show significant generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving cholinesterase inhibitor therapy and immunosuppressant therapy (IST) and who require chronic plasma exchange or chronic IVIg to maintain clinical stability. In other embodiments, refractory generalized myasthenia gravis is characterized as including subjects or patients who continue to show significant generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving cholinesterase inhibitor therapy and immunosuppressant therapy (IST) and who require chronic plasma exchange or chronic IVIg to maintain clinical stability.
[0061] As used herein, the phrase "requiring chronic plasma exchange" to maintain clinical stability refers to the use of plasma exchange therapy in a patient on a regular basis for the management of muscle weakness at least every 3 months during the last 12 months.
[0062] As used herein, the phrase "requiring chronic IVIg" to maintain clinical stability refers to the use of IVIg treatment in a patient on a regular basis for management of muscle weakness at least every 3 months over the last 12 months.
[0063] In certain embodiments, treatment of MG includes amelioration or improvement of one or more symptoms associated with MG. Symptoms associated with MG include muscle weakness and fatigue. Muscles primarily affected by MG include those involved in eye and eyelid movement, facial expression, chewing, speaking, swallowing, breathing, and the like. These include the muscles that control sucking, neck movement, and leg movement.
[0064] In other embodiments, the treatment of MG includes improving clinical markers for MG progression.These markers include MG Activities of Daily Living Profile (MG-ADL), quantitative myasthenia gravis (QMG) score for disease severity, myasthenia gravis composite (MGC), negative inspiratory force (NIF), forced vital capacity, MGFA post-intervention status, and other quality of life measures.In certain embodiments, MG-ADL is the main score for measuring the improvement of MG.
[0065] The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living (ADL) in MG subjects (see Table 1). The 8 items of the MG-ADL were derived from the symptom-based components of the original 13-item QMG to assess impairments secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) functional impairments related to the effects from MG. In this functional status instrument, each response is graded from 0 (normal) to 3 (most severe). The range of the total MG-ADL score is 0-24. A clinically meaningful improvement in a patient's MG-ADL would be a 3-point or greater reduction in score after 26 weeks of treatment.
[0066] The current QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item); each graded from 0 to 3, with 3 being the most severe (see Table 2). The total QMG score ranges from 0 to 39. The QMG scoring system is considered to be an objective evaluation of the treatment of MG and is based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective trials of the treatment of MG. A clinically meaningful improvement in a patient's QMG would be a 5-point or greater reduction in score after 26 weeks of treatment.
[0067] [Table 1]
[0068] [Table 2]
[0069] The MGC is a validated assessment tool to measure the clinical status of subjects with MG (16). The MGC assesses 10 important areas of functioning most frequently affected by MG, and the scale is weighted for clinical significance incorporating subject-reported outcomes. See Table 3. The MGC is administered at Screening, Days 1, 1–4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 110, 1 Treatment is administered at Weeks 16, 20, and 26 or ET (Visits 1-6, 8, 10, 12, 14, and 17 or ET). A clinically meaningful improvement in a patient's MGC would be a 3 or greater point reduction in score after 26 weeks of treatment.
[0070] [Table 3]
[0071] The 15-item Myasthenia Gravis Quality of Life 15 scale (MG-QOL 15) is an assessable health-related quality of life instrument specific to subjects with MG. See Table 4. The MG-QOL 15 was designed to provide information about the subject's sense of impairment and disability, and the degree to which disease symptoms are tolerated, and to be easy to administer and explain. Total scores range from 0 to 60. Higher scores translate to a higher degree of patient dissatisfaction with MG-related dysfunction. The MG-QOL 15 is completed in full by the subject. Higher scores indicate a higher degree and dissatisfaction with MG-related dysfunction. A clinically meaningful improvement in a patient's MG-QOL 15 would be a reduction in score after 26 weeks of treatment.
[0072] [Table 4]
[0073] The Neuro-QOL Fatigue is a reliable and validated short 19-item fatigue survey completed by the subject. Higher scores indicate more severe fatigue and a greater impact of MG on activity (see Table 5). A clinically meaningful improvement in a patient's Neuro-QQL Fatigue score would be reflected by a reduction in score after 26 weeks of treatment.
[0074] [Table 5]
[0075] The EUROQOL (EQ-5D) is a reliable and valid survey completed by the subject of health status in five domains: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each domain has three levels: Level 1 ( Level 1 (no problems), Level 2 (some problems), and Level 3 (very problems) (see Figures 2A and 2B). The EQ VAS records the subject's self-assessed health on a vertical 20 cm visual analog scale, where the endpoints are labeled "best imaginable health" marked with "100" and "worst imaginable health" marked with 0. The EQ-5D is administered at Day 1, Weeks 4, 8, 12, 16, 20, and 26 or ET (Visits 2, 6, 8, 10, 12, 14, and 17 or ET). A clinically meaningful improvement in a patient's EQ-5D will be reflected as an increase in score after 26 weeks of treatment.
[0076] Subjects with increasingly severe MG may suffer from potentially fatal respiratory complications, including severe respiratory muscle weakness. Respiratory function is closely monitored for evidence of respiratory failure in MG subjects, and ventilatory support is recommended in the event of a consistent decline in graded measurements of Forced Vital Capacity (FVC) or Negative Inspiratory Force (NIF), loss of upper airway integrity (difficulty managing oral secretions, swallowing, or speaking), or in the setting of emerging respiratory failure. FVC, as one of the test components of QMG, is performed when QMG is performed. NIF is performed using a NIF meter.
[0077] MG clinical status will be assessed using the MGFA post-intervention status. Changes in status categories of MG improved, unchanged, worsened, exacerbated and death, as well as Minimal Manifestation (MM) can be assessed.
[0078] According to certain embodiments, patients administered eculizumab show reduced MG-ADL. In certain embodiments, the subject has an initial MG-ADL score of more than 6 points. In other embodiments, the subject has an initial MG-ADL score of more than 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 points. In certain embodiments, after a course of treatment with eculizumab, the subject's MG-ADL score is reduced to less than 6 points. In other embodiments, the MG-ADL score is reduced by at least 1 point, at least 2 points, at least 3 points, at least 4 points, at least 5 points, at least 6 points, at least 7 points, at least 8 points, at least 9 points, at least 10 points, at least 11 points, at least 12 points, at least 13 points, at least 14 points, at least 15 points, at least 16 points, at least 17 points, at least 18 points, at least 19 points, at least 20 points, at least 21 points, at least 22 points, at least 23 points, or at least 24 points after treatment with eculizumab. In certain embodiments, the patient's MG-ADL score is reduced by at least 1 point after a course of treatment with eculizumab. In other embodiments, the patient's MG-ADL decreases by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 points after a course of treatment with eculizumab.
[0079] According to certain embodiments, the course of treatment with eculizumab lasts for 26 weeks. According to other embodiments, the course of treatment lasts for 26-52, 26-78, 26-104, 26-130, 26-156, 26-182, 26-208 weeks or more. In other embodiments, the course of treatment lasts for more than 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 78, 104, 130, 156, or 182 weeks. According to other embodiments, the course of treatment is longer than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 years or more. In certain embodiments, the course of treatment continues for the remainder of the subject's life.
[0080] In certain embodiments, during the course of treatment, one or more symptoms or scores associated with MG improve during the course of treatment and are maintained at an improved level throughout the treatment. For example, MG-ADL may improve after 26 weeks of treatment with a therapeutic antibody that specifically binds C5 and then remain at an improved level for the duration of treatment, which is 52 weeks of treatment with a therapeutic antibody that specifically binds C5. One example of a therapeutic antibody that binds C5 is eculizumab.
[0081] In certain embodiments, the first signs of improvement occur by 26 weeks of treatment with a therapeutic antibody that specifically binds C5. According to other embodiments, the first signs of improvement occur between 1-26, 26-52, 52-78, 78-104, 104-130, 130-156, 156-182, or 182-208 weeks of treatment with a therapeutic antibody that specifically binds C5. In other embodiments, the first signs of improvement occur at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 78, 104, 130, 156, or 182 weeks.
[0082] According to certain embodiments, the initial signs of improvement are maintained for a number of weeks during treatment with a binding protein that specifically binds C5, such as eculizumab or an eculizumab variant such as BNJ441. According to certain embodiments, this number of weeks is at least 26. According to other embodiments, this number of weeks is 1 to 26, 26 to 52, 52 to 78, 78 to 104, 104 to 130, 130 to 156, 156 to 182, or 182 to 208. In other embodiments, the number of weeks is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 78, 104, 130, 156, or 182.
[0083] According to certain embodiments, eculizumab or other anti-C5 antibodies such as BNJ441, BNJ421, 7086, and 8110 may be administered between 600 and 6000 mg to a subject suffering from MG. According to other embodiments, the induction dose of eculizumab or other anti-C5 antibodies such as BNJ441, BNJ421, 7086, and 8110 is between 900 and 1500 mg, between 900 and 1200 mg, 900 mg, or 1200 mg. In other embodiments, the maintenance dose of eculizumab or other anti-C5 antibodies, such as BNJ441, BNJ 421, 7086, and 8110, is about 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 4000, 5000, or 6000 mg.
[0084] These doses can be administered monthly, biweekly, weekly, twice weekly, or daily. According to certain embodiments, the doses are administered biweekly or weekly. According to other embodiments, eculizumab is administered to subjects suffering from MG in a multi-phase dosing regimen. According to certain embodiments, the multi-phase dosing regimen has 2, 3, 4, 6, 7, 8, 9, 10, or more phases. In certain embodiments, each phase provides a higher dose than the previous phase.
[0085] In certain embodiments, the eculizumab multiphase dosing regimen has two phases. The first phase is the induction phase. This phase is 600, 900, 1200, 1500, or provides a dose of 1800 mg. In certain embodiments, this phase lasts for 2, 3, 4, 5, 6, 7, 8, 9, or 10 weeks. In other embodiments, this phase lasts between 2 and 6 weeks. In other embodiments, the phase lasts for 5 weeks. According to certain embodiments, the dose administered in any week is higher than the previous week. In other embodiments, the dose remains the same for a number of weeks and is then increased. In some embodiments, the dose remains the same for the first 1, 2, 3, 4, 5, 6, 7, 8, or 9 weeks and is then increased. In other embodiments, the dose remains the same for the first 4 weeks. According to some embodiments, the eculizumab dose is administered between 600 and 1200 mg, between 800 and 1500 mg, between 900 and 1200 mg, between 900 and 1100 mg, between 900 and 1000 mg, between 800 and 1000 mg, between 800 and 1100 mg, or between 800 and 1200 mg for multiple weeks and then increased thereafter. In one embodiment, the eculizumab dose is administered at about 900 mg on day 1, followed by 900 mg on day 7, 900 mg on day 14, 900 mg on day 21, then increased to 1200 mg for the fifth dose on day 28, and 1200 mg every 14±2 days thereafter.
[0086] In one particular embodiment, the eculizumab induction phase dosing regimen includes five doses administered on the following schedule: 900 mg on day 1; 900 mg on day 7 (week 1); 900 mg on day 14 (week 2), 900 mg on week 21 (week 3), and 1200 mg on day 28 (week 4), then 1200 mg every 14 ± 2 days. The actual number of days between each dose may vary during the lead-in by 1 or 2 days to accommodate unforeseen events in the patient's schedule.
[0087] According to this embodiment, the second phase of eculizumab dosing is a maintenance phase. The maintenance phase of eculizumab dosing can last between 6 weeks and the lifespan of the subject. According to other embodiments, the maintenance phase lasts for 26-52, 26-78, 26-104, 26-130, 26-156, 26-182, 26-208 weeks or more. In other embodiments, the maintenance phase lasts for more than 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 78, 104, 130, 156, or 182 weeks. According to other embodiments, the maintenance phase lasts for 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 years or more. In certain embodiments, the maintenance phase lasts for the remainder of the subject's lifespan.
[0088] In certain embodiments, the eculizumab multiphase dosing regimen includes a third phase. This third phase is used when MG patients must undergo a rescue procedure to maintain clinical stability and includes administering plasma exchange and / or administering IVIg. In this phase, after the plasma is exchanged, a dose of eculizumab is administered to replace the drug lost in the plasma exchange. According to certain embodiments, this post-rescue eculizumab dose is between 300 and 1200 mg, between 400 and 1500 mg, between 500 and 1000 mg, between 400 and 800 mg, or between 500 and 700 mg. According to certain embodiments, this post-rescue eculizumab dose is about 600 mg. In another embodiment, in this post-rescue or third phase, a 600 mg eculizumab dose is administered within 1 hour after completion of plasmapheresis. In another embodiment, in the third stage, a 600mg dose is administered within 2 hours after completion of plasmapheresis.In another embodiment, in the third stage, a 600mg dose is administered within 3 hours after completion of plasmapheresis.In another embodiment, in the third stage, a 600mg dose is administered within 4 hours after completion of plasmapheresis.In another embodiment, in the third stage, a 600mg dose is administered within 5 hours after completion of plasmapheresis.In another embodiment, in the third stage, a 600mg dose is administered within 6 hours after completion of plasmapheresis.
[0089] 2. Pharmaceutical Compositions Provided herein are pharmaceutical compositions comprising eculizumab, alone or in combination with a prophylactic agent, a therapeutic agent, and / or a pharmaceutically acceptable carrier. Provided herein are pharmaceutical compositions comprising eculizumab for use in preventing, treating, managing, or ameliorating a disorder or one or more symptoms thereof, and / or in diagnosing, detecting, or monitoring a disorder. Formulation of pharmaceutical compositions, alone or in combination with a prophylactic agent, a therapeutic agent, and / or a pharmaceutically acceptable carrier, is known to those skilled in the art.
[0090] An exemplary non-limiting range of a therapeutically or prophylactically effective amount of eculizumab or other anti-C5 antibodies such as BNJ441, BNJ 421, 7086, and 8110 provided herein is 600-5000 mg, e.g., 900-2000 mg. It should be noted that dosage values may vary depending on the type and severity of the condition to be alleviated. It should further be understood that for any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the composition, and dosage ranges set forth herein are illustrative only and are not intended to limit the scope or practice of the claimed methods.
[0091] 3. Combination Therapy The anti-C5 antibodies provided herein can also be administered with one or more additional agents or therapeutic agents useful in the treatment of MG. For example, the additional agent can be an art-recognized therapeutic agent useful for treating myasthenia gravis or a condition treated by the antibodies provided herein. The combination can also include more than one additional agent, for example, two or three additional agents.
[0092] In various embodiments, the binding agent is administered with a protein, peptide, carbohydrate, drug, small molecule, or genetic material (e.g., DNA or RNA). In various embodiments, the agent is one or more cholinesterase inhibitors, one or more corticosteroids, and / or one or more immunosuppressants (most commonly azathioprine [AZA], cyclosporine, and / or mycophenolate mofetil [MMF]).
[0093] Without limiting the disclosure, numerous embodiments of the disclosure are described below for purposes of illustration.
[0094] Item 1: A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an anti-complement component 5 (C5) antibody or antigen-binding fragment thereof, wherein the patient is administered the anti-C5 antibody or antigen-binding fragment thereof for at least 26 weeks.
[0095] Item 2: A method of treating refractory generalized myasthenia gravis in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an anti-C5 antibody or antigen-binding fragment thereof, wherein the anti-C5 antibody or antigen-binding fragment thereof is eculizumab or an eculizumab variant; and The above method, wherein the patient is administered eculizumab or an eculizumab variant for at least 26 weeks.
[0096] Item 3: Patients test positive for autoantibodies binding to nicotinic acetylcholine receptors (anti-AChR) and have significant generalized weakness or bulbar signs and severe myasthenia while receiving treatment for myasthenia gravis, including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST). exhibiting symptoms of myasthenia and requiring chronic plasma exchange or chronic IVIg to maintain clinical stability; and 3. The method of item 1 or 2, wherein the patient is administered eculizumab for at least 26 weeks.
[0097] Item 4: A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient: wherein the patient is positive for autoantibodies binding to nicotinic acetylcholine receptors (anti-AChR) and exhibits significant generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability; Eculizumab is administered using a phased dosing schedule that includes an induction phase comprising a 900 mg induction dose of eculizumab administered on day 1, 900 mg doses of eculizumab administered on days 7, 14, and 21, and 1200 mg of eculizumab administered as a fifth induction dose on day 28; and The above method, wherein the patient is administered eculizumab for at least 26 weeks.
[0098] Item 5: The method of any one of items 1-4, wherein the 28 day induction phase of eculizumab treatment is followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose, and administering 1200 mg of eculizumab every 14 ± 2 days thereafter.
[0099] Item 6: The method of any one of items 1 to 5, wherein the dosing regimen further comprises a third phase.
[0100] Item 7: The method of any one of items 1 to 6, wherein the third step comprises performing plasmapheresis on the patient and administering eculizumab at a dose of between 300 mg and 1200 mg to the patient within 4 hours of completion of the plasmapheresis.
[0101] Item 8: The method of any one of items 1 to 7, wherein the third step includes performing plasmapheresis on the patient and administering eculizumab at a dose of between 600 mg and 900 mg to the patient within 90 minutes of completion of the plasmapheresis.
[0102] Item 9: The method of any one of items 1 to 8, comprising performing plasmapheresis on the patient and administering eculizumab at a dose of 600 mg to the patient within 1 hour of completion of the plasmapheresis.
[0103] Item 10: The method of any one of items 1 to 9, wherein the patient experiences a clinically significant improvement (reduction) in Myasthenia Gravis Activities of Daily Living (MG-ADL) after 26 weeks of treatment.
[0104] Item 11: The method of any one of items 1 to 10, wherein the clinically meaningful improvement experienced by the patient is at least a 3 point reduction in the patient's MG-ADL score after 26 weeks of treatment.
[0105] Item 12: The method of any one of items 1 to 11, wherein the clinically meaningful improvement experienced by the patient is at least a 4 point reduction in the patient's MG-ADL score after 26 weeks of treatment.
[0106] Item 13: The method of any one of items 1 to 12, wherein the patient experiences a clinically meaningful improvement (reduction) in Quantitative Myasthenia Gravis Score (QMG) after 26 weeks of treatment.
[0107] Item 14: The method of any one of items 1 to 13, wherein the clinically meaningful improvement experienced by the patient is at least a 4-point reduction in the patient's QMG after 26 weeks of treatment.
[0108] Item 15: The method of any one of items 1 to 14, wherein the clinically meaningful improvement experienced by the patient is at least a 5 point reduction in the patient's QMG score after 26 weeks of treatment.
[0109] Item 16: The method of any one of items 1 to 15, wherein the patient experiences a clinically meaningful improvement (reduction) in Myasthenia Gravis Composite (MGC) score after 26 weeks of treatment.
[0110] Item 17: The method of any one of items 1 to 16, wherein the clinically meaningful improvement experienced by the patient is at least a 6 point reduction in the patient's MGC score after 26 weeks of treatment.
[0111] Item 18: The method of any one of items 1 to 17, wherein the clinically meaningful improvement experienced by the patient is at least a 10 point reduction in the patient's MGC score after 26 weeks of treatment.
[0112] Item 19: The method of any one of items 1 to 18, wherein the patient experiences a clinically meaningful improvement in quality of life as measured by Myasthenia Gravis Quality of Life (MG-QOL-15) score after 26 weeks of treatment.
[0113] Item 20: The method of any one of items 1 to 19, wherein the clinically meaningful improvement experienced by the patient is at least a 6 point reduction in the patient's MG-QOL-15 score after 26 weeks of treatment.
[0114] Item 21 : The method of any one of items 1 to 20, wherein the clinically meaningful improvement experienced by the patient is at least an 11 point reduction in the patient's MG-QOL-15 score after 26 weeks of treatment.
[0115] Item 22: The method according to any one of items 1 to 21, wherein the patient experiences a clinically significant improvement (reduction) in neuro-fatigue as measured by the Neuro-QOL Fatigue score after 26 weeks of treatment.
[0116] Item 23: The method of any one of items 1 to 22, wherein the clinically meaningful improvement experienced by the patient is at least an 8 point reduction in the patient's Neuro-QOL score after 26 weeks of treatment.
[0117] Item 24: The method of any one of items 1 to 23, wherein the clinically meaningful improvement experienced by the patient is at least a 16 point reduction in the patient's Neuro-QOL score after 26 weeks of treatment.
[0118] Item 25: The method of any one of items 1 to 24, wherein the patient experiences a clinically meaningful improvement (increase) in health status as measured by EQ-5D health status score after 26 weeks of treatment.
[0119] Item 26: In patients in need thereof, including administering eculizumab to patients 1. A method for treating refractory generalized myasthenia gravis comprising: wherein the patient is positive for autoantibodies binding to nicotinic acetylcholine receptors (anti-AChR) and exhibits significant generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability; wherein eculizumab is administered using a phased dosing schedule comprising administering a 900 mg induction dose of eculizumab on day 1, administering 900 mg doses of eculizumab on days 7, 14, and 21, and administering 1200 mg of eculizumab as a fifth dose on day 28; A 28-day induction phase of eculizumab treatment followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose, and 1200 mg of eculizumab every 14 ± 2 days thereafter; and The patient has a clinically meaningful improvement (reduction) in at least two measures of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL. The above method.
[0120] Item 27: A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient: wherein the patient is positive for autoantibodies binding to nicotinic acetylcholine receptors (anti-AChR) and exhibits significant generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability; Eculizumab is administered using a phased dosing schedule including a 900 mg induction dose of eculizumab administered on day 1, 900 mg doses of eculizumab administered on days 7, 14, and 21, and 1200 mg of eculizumab administered as a fifth induction dose on day 28; Patients received eculizumab for at least 26 weeks; A 28-day induction phase of eculizumab treatment followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose, and 1200 mg of eculizumab every 14 ± 2 days thereafter; and The patient has a clinically meaningful improvement (reduction) in at least three measures of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL. The above method.
[0121] Item 28: The method of any one of items 1 to 27, wherein the patient has a clinically significant improvement (reduction) in at least four measurements of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL.
[0122] Item 29: The method of any one of items 1 to 28, wherein the patient has a clinically meaningful improvement (reduction) in five measures of generalized myasthenia gravis severity, wherein the five measures of generalized myasthenia gravis severity are MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL.
[0123] Item 30: A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient: wherein the patient is positive for autoantibodies binding to nicotinic acetylcholine receptors (anti-AChR) and exhibits significant generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability; Eculizumab is administered using a phased dosing schedule including a 900 mg induction dose of eculizumab administered on day 1, 900 mg doses of eculizumab administered on days 7, 14, and 21, and 1200 mg of eculizumab administered as a fifth induction dose on day 28; Patients received eculizumab for at least 26 weeks; A 28-day induction phase of eculizumab treatment followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose, and 1200 mg of eculizumab every 14 ± 2 days thereafter; and The patient has a clinically meaningful improvement (reduction) in five measures of generalized myasthenia gravis severity, where the five measures of generalized myasthenia gravis severity are a reduction of at least 3 points in MG-ADL, a reduction of at least 4 points in QMG, a reduction of at least 6 points in MGC, a reduction of at least 6 points in MG-QOL, and a reduction of at least 8 points in Neuro-QOL. The above method.
[0124] Item 31: The method of any one of items 1 to 30, wherein the patient has a clinically meaningful improvement (reduction) in five measures of generalized myasthenia gravis severity, wherein the five measures of generalized myasthenia gravis severity are a reduction of at least 4 points in MG-ADL, a reduction of at least 5 points in QMG, a reduction of at least 10 points in MGC, a reduction of at least 11 points in MG-QOL, and a reduction of at least 16 points in Neuro-QOL.
[0125] Item 32: The method of any one of items 1 to 31, wherein eculizumab is administered by intravenous infusion.
[0126] Item 33: The method of any one of Items 1 to 32, wherein eculizumab is administered subcutaneously.
[0127] Item 34: The method according to any one of Items 1 to 33, wherein the eculizumab comprises a heavy chain amino acid sequence according to SEQ ID NO: 10 and a light chain amino acid sequence according to SEQ ID NO: 11.
[0128] Item 35: The method according to any one of Items 1 to 34, wherein the eculizumab is an eculizumab variant comprising a heavy chain amino acid sequence according to SEQ ID NO: 14 and a light chain amino acid sequence according to SEQ ID NO: 11.
[0129] Item 36: The method according to any one of Items 1 to 35, wherein the eculizumab is an eculizumab variant comprising a heavy chain variable region amino acid sequence according to SEQ ID NO: 12 and a light chain amino acid sequence according to SEQ ID NO: 11.
[0130] Item 37: The method according to any one of Items 1 to 36, wherein the anti-C5 antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence according to SEQ ID NO: 27 and a light chain variable region amino acid sequence according to SEQ ID NO: 28.
[0131] Item 38: The anti-C5 antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence according to SEQ ID NO: 35 and a light chain variable region amino acid sequence according to SEQ ID NO: 36, 37. The method according to any one of claims 37.
[0132] Item 39: The method of any one of items 1 to 38, wherein the patient has failed treatment with two or more ISTs in sequence or in combination for one or more years.
[0133] Item 40: The method according to any one of items 1 to 39, wherein the patient has failed at least one IST and requires chronic plasma exchange or IVIg to control symptoms of myasthenia gravis.
[0134] Item 41: A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient: wherein the patient is positive for autoantibodies binding to nicotinic acetylcholine receptor (anti-AChR) and shows marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST), and wherein the patient has previously failed treatment with at least two immunosuppressants or has failed treatment with at least one immunosuppressant and requires chronic plasma exchange or IVIg, and has an MG-ADL total score of ≧6 at study entry; wherein eculizumab is administered using a phased dosing schedule comprising administering a 900 mg induction dose of eculizumab on day 1, administering 900 mg doses of eculizumab on days 7, 14, and 21, and administering 1200 mg of eculizumab as a fifth induction dose on day 28; Patients received eculizumab for at least 26 weeks; A 28-day induction phase of eculizumab treatment followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose, and 1200 mg of eculizumab every 14 ± 2 days thereafter; and The patient has a clinically meaningful improvement (reduction) in at least two measures of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, and MGC. The above method.
[0135] Item 42: The method according to any one of Items 1 to 41, wherein the therapeutically effective amount of eculizumab or eculizumab variant administered to the patient is maintained at a concentration of between 50 and 100 μg / mL in the patient's serum.
[0136] Item 43: The method according to any one of items 1 to 42, wherein the patient experiences discontinuation of administration of one or more ISTs after at least 26 weeks of treatment.
[0137] Item 44: The method of any one of items 1 to 43, wherein the patient experiences a reduction in IST dosing after at least 26 weeks of treatment.
[0138] Item 45: The method according to any one of items 1 to 44, wherein the patient experiences a reduction in one or more IST dosages and a discontinuation of one or more ISTs after at least 26 treatments. EXAMPLES
[0139] Example 1: Efficacy of eculizumab in treating myasthenia gravis in human subjects. The primary objective of this study is to evaluate the efficacy of eculizumab compared with placebo in the treatment of refractory gMG based on improvements in the MG-specific Activities of Daily Living Profile (MG-ADL).
[0140] Secondary objectives of this study include: - Characterize the overall safety and tolerability of eculizumab compared to placebo in gMG subjects - Evaluate the efficacy of eculizumab compared to placebo with additional efficacy measures including: Quantitative MG (QMG) score for disease severity Myasthenia Gravis Composite (MGC) Improvement in the primary symptom that is most clinically significant to the subject Ocular, Respiratory, Limb and Eye MG-ADL subcategories - Characterize the effects of eculizumab compared with placebo on quality of life measures - Describe the PK and PD of eculizumab in gMG subjects.
[0141] 1. Clinical trial plan 1.1 Overall Study Design and Planning Described herein is a randomized, double-blind, parallel-group, placebo-controlled, multicenter (approximately 100 sites in North America, South America, Europe, and Asia-Pacific) approximately 2-year study to evaluate the safety and efficacy of eculizumab for treatment in subjects with refractory gMG. Approximately 92 eligible subjects were randomized on day 1 in a 1:1 ratio to one of two treatment arms: (1) eculizumab infusion or (2) placebo infusion. Subjects may continue to receive a stable dose / type of immunosuppressant therapy (IST), but no new IST or increases in IST dosage will be allowed during the study. The study has three periods: screening, study, and follow-up (for subjects who discontinue the study or do not participate in the extension study). See Figure 1. The overall study duration for an individual subject is estimated to take up to 38 weeks, including enrollment and follow-up. Subjects may be given the opportunity to participate in an extension study (separate protocol) to receive eculizumab after completion of this study. The assessment schedule for the screening, study, and follow-up phases is shown in Table 6.
[0142] 1.1.1. Screening period (weeks 2-4) At the screening visit, after obtaining informed consent from the subject, the subject will be screened for a medical history review, demographic data, and laboratory evaluations. The medical history review will include confirmation of MG diagnosis as defined in the inclusion criteria of this protocol, previous treatments / treatments for MG, e.g., thymectomy, IST including corticosteroids, IVIg, and plasma exchange, history of MG exacerbations or crises including duration of each exacerbation / crisis, medications administered at the time of each exacerbation / crisis, and treatment for each exacerbation / crisis.
[0143] If all inclusion criteria are met and no exclusion criteria are met, subjects will be vaccinated against N. meningitidis if they have already been vaccinated within the active coverage period specified by the vaccine manufacturer or have not been vaccinated according to current medical / national guidelines. Subjects must be vaccinated at least 14 days prior to receiving the first dose of study drug, and must be vaccinated and treated with appropriate antibiotics for at least 14 days after vaccination. See Figure 3.
[0144] The use of cholinesterase inhibitors and supportive IST is permitted during the trial with certain restrictions (see Concomitant Medications below). The washout period for IVIg is 4 weeks prior to randomization. The washout period for PE is also 4 weeks prior to randomization. If the subject experiences a MG crisis during the screening period, the sponsor must be informed. After discussion with the sponsor, it will be decided whether the subject may continue in the trial, be discontinued, and possibly be rescreened at a later date.
[0145] [Table 6]
[0146] [Table 7]
[0147] Randomization Vaccinated and met the MG-ADL enrollment criteria, i.e., M All subjects who continue to meet a G-ADL total score ≧6 and are cleared for randomization by their respective Principal Investigator (PI) will be randomized to the eculizumab or placebo arm on a 1:1 basis on Day 1. Randomization stratification will be based on assessment of the Myasthenia Gravis Foundation of America (MGFA) (see Table 7) clinical classification performed at the screening visit according to the following four groupings: a. MGFA Class IIa and IIIa b. MGFA Class IVa c. MGFA classes IIb and IIIb, and d. MGFA Class IVb
[0148] 1.1.3. Study duration (26 weeks) Subjects will receive either IP, eculizumab or placebo according to the regimen described in Randomization and Investigational Product and Administration below. The treatment period for each subject will be 26 weeks. Subjects must be informed of the potential signs and symptoms of MG crisis and will be instructed to contact the Investigator as soon as possible upon onset of symptoms. Every effort will be made for subjects to report clinical progression to be evaluated as soon as possible and within 48 hours of the Investigator's knowledge of the onset of symptoms. At the evaluation visit, the Investigator or his / her designee will conduct the evaluations specified by this protocol. The Investigator will determine whether the subject meets the definition of clinical progression as defined by this protocol and will treat the subject accordingly.
[0149] [Table 8]
[0150] After completing the 26-week study period, subjects may be offered the opportunity to enroll in an extension study (separate protocol) to receive open-label eculizumab. The visit interval between this study and the extension study is 2 weeks from the last IP dose (Visit 17), so there is no interruption of IP dosing. Subjects enrolled in the extension study will undergo a blinded eculizumab induction period similar to the induction in this study in order to maintain their blinded treatment assignment in this study. If a subject discontinues this study after receiving any amount of IP, or does not wish to enter the extension study after completion of this study, the subject will be required to complete a follow-up visit for safety measures.
[0151] 1.1.4. Follow-up period (8 weeks after treatment) If a subject discontinues or is withdrawn from the study after receiving any amount of IP If a subject discontinues due to an AE, or does not wish to enter the extension study after completion of this study, the subject will be required to complete a follow-up visit 8 weeks after the last IP dose for safety purposes. If a subject discontinues due to an AE, the event will be followed until it is resolved or, in the opinion of the PI, is medically stable.
[0152] 1.2. Standard Protocol Definition Abbreviations and definitions for the studies and follow-up periods are shown in Table 8.
[0153] [Table 9]
[0154] [Table 10]
[0155] 1.2.1. Clinical deterioration For this protocol, clinical progression is defined as follows: Subjects who experience MG crisis, defined as MG-related weakness severe enough to require intubation or delay postoperative extubation. Respiratory failure is due to respiratory muscle weakness. Severe bulbar (oropharyngeal) muscle weakness often accompanies respiratory muscle weakness or may be the predominant feature in some subjects; or Significant symptom worsening to a score of 3 or 2 points worse on any one of the individual MG-ADL items other than diplopia or ptosis; or Subjects where the treating physician believes that the subject's health is at risk if rescue treatment is not provided (e.g. emergency situations).
[0156] Clinical evaluation Clinical assessors are study staff trained and qualified to perform MG-ADL, QMG and MGC. Clinical assessors may be neurologists, physiotherapists or other study team members selected by the PI. Clinical assessor training and certification for this protocol will be conducted at the investigator meeting or via the sponsor designated online training portal 1.2.3.
[0157] Responsibility for MG evaluation Responsibilities for MG assessment are listed in Table 9. Throughout the study, MG assessments should be performed at approximately the same time of day by an appropriately trained assessor, preferably the same assessor.
[0158] [Table 11]
[0159] 1.4. Study Visit Procedures 1.4.1. Screening visit (Before baseline, days -28 to -14 [Visit 2 / Day 1]) After obtaining a signed informed consent form, the following tests and assessments will be performed at the Baseline Visit (Visit 2 / Day 1) within 2-4 weeks prior to randomization to determine the subject's eligibility for participation in this study: Review inclusion and exclusion criteria; Enroll subjects in the IXRS system to obtain a study subject identification number and initiate drug shipping if necessary; Record medical history and demographics; Record MGFA clinical classification Record your MG medical history: Confirm the diagnosis of MG as defined by protocol inclusion criterion number 2 b. Record the initial clinical manifestation of MG (i.e., oMG or gMG). If the initial clinical manifestation was oMG, record the time (date) to onset of gMG. c. Record maximum MGFA classification from diagnosis, if available. d. Record whether the subject has ever required ventilatory support since diagnosis e. Record the number of ICU stays (days) and hospitalizations, including any ventilatory support associated with hospitalization, within the 2 years prior to screening. f. Record the number and duration of all previous MG exacerbations or, if applicable, record all previous MG exacerbations or crises, medications / treatments received at the time of each exacerbation or crisis, and the use of medications / treatments to treat each exacerbation or crisis. Record MG treatment status (see Table 9) Measure your weight and height Measure vital signs, including assessment of systolic and diastolic blood pressure (BP), temperature, respiratory rate (RR) and heart rate (HR) · Complete a physical examination including evaluation of the following organs / body systems: skin, head, ears, eyes, nose, throat, neck, lymph nodes, chest, heart, abdomen, extremities, musculoskeletal, and general neurological examination. Perform a 12-lead ECG Record concomitant medications, including prior IST, IVIg, and / or PE for MG from the time of diagnosis through screening, as well as all other concomitant medications within 30 days prior to the screening visit. The MG-ADL will be administered by appropriately trained assessors. The recall period will be the previous 7 days. · Perform clinical assessments QMG, NIF, and MGC; these should be performed at approximately the same time of day by appropriately trained assessors. If the subject is taking a cholinesterase inhibitor, the medication must be withheld for at least 10 hours prior to the QMG and MGC tests. · Evaluate quality of life by administering the MG-QOL15 questionnaire. Obtain a blood sample for AChR Ab testing. Obtain blood samples for laboratory testing (chemistry and hematology) (see Table 6) · Obtain a pregnancy test (serum) for all females of childbearing potential. Note: If the subject is taking / using a contraceptive medication / device, be sure to record the medication or device on the appropriate electronic Case Report Form (eCRF) page (Concomitant Medications or Procedures). If all inclusion criteria and none of the exclusion criteria are met, the subject will be vaccinated against N. meningitidis if they have not already been vaccinated within the period of activity coverage specified by the vaccine manufacturer or according to current medical / national guidelines. Subjects must be vaccinated at least 14 days before receiving the first dose of investigational product, or vaccinated and treated with an appropriate antibiotic until at least 14 days after vaccination. If a subject experiences an MG crisis during the Screening Period, the sponsor must be notified. After discussion with the sponsor, a decision will be made as to whether the subject may continue in the study, be withdrawn, and possibly re-screened at a later date.
[0160] 1.4.2. Test period The visit interval during the induction phase (Visits 2, 3, 4, 5, and 6) is weekly (every 7 ± 2 days after the last visit). The visit interval during the maintenance phase (Visits 7-17) is every 2 weeks (every 14 ± 2 days after the last visit). Subjects who fail to return for a scheduled visit should be contacted by site study staff to determine the reason for the missed appointment. If clinical progression or AE is suspected to have occurred, the subject will be strongly encouraged to return to the investigational site for evaluation. In the exceptional situation where a subject cannot or will not come to the investigational site for examination, the subject will be instructed to see his or her local neurologist or physician. In this event, the investigational site will obtain relevant medical records as documentation from the local physician's examination and enter the relevant data into the eCRF as appropriate.
[0161] [Table 12]
[0162] It is very important to obtain information regarding subjects' missed visits to ensure that the missed appointments were not due to clinical progression or AEs, so every effort must be made to initiate the follow-up procedures specified in the protocol (see Table 6). Follow-up due diligence documentation consisted of three telephone contacts followed by one registered mail to the subject's last known address. The study duration is summarized in Table 6 and Figure 6.
[0163] 1.4.2.1. Run-in phase (Baseline [Visit 2 / Day 1] to Visit 6 [Week 4]) 1.4.2.1.1. Baseline (Visit 2 / Day 1) Once all of the eligibility criteria are confirmed by the PI, subjects will be randomly assigned on Day 1. The following tests and procedures will be completed at the Baseline Visit (Visit 2 / Day 1): Measure vital signs, including assessment of systolic and diastolic BP, temperature, RR and HR Record MG treatment status (see Table 9) Record any new medications or changes to concomitant medications Assess and record AEs from the previous visit Administer questions to assess quality of life (MG-QOL 15, Neuro-QOL Fatigue, and EuroQoL [EQ-5D]) · MG-ADL will be administered by an appropriately trained assessor, preferably the same assessor throughout the study. The recall period will be the previous 7 days. If the number of days since the last visit is <7, the recall period will be from the last visit. · Perform clinical assessments QMG, NIF, and MGC; these should be performed at approximately the same time of day by a trained assessor, preferably the same assessor throughout the study. If subjects are taking cholinesterase inhibitors, the medication must be withheld for at least 10 hours prior to QMG and MGC testing. Administer the Columbia-Suicide Rating Scale (C-SSRS) Obtain blood samples for clinical laboratory tests (chemistry and hematology) · Obtain pregnancy tests (serum) for all women of childbearing potential. Collect baseline blood samples 5-90 minutes prior to IP infusion for PK, PD, free C5, and HAHA assays. Instruct subjects regarding the signs and symptoms of N. meningitis. Provide subjects with a Patient Safety Information Card containing the IP and emergency contact information prior to the first dose of IP. Randomize subjects using the IXRS. Administer an IP infusion over approximately 35 minutes according to the regimen described in Section 4.5, and observe the subject for 1 hour following completion of the IP infusion. Collect peak blood samples for PK, PD, and free C5 assays at least 60 minutes after completion of the IP infusion.
[0164] 1.4.2.1.2. Visit 3-5 (1-3 weeks) The following tests and procedures were completed: Measure vital signs, including assessment of systolic and diastolic BP, temperature, RR, and HR Record any new medications or changes to concomitant medications Assess and record any new or change in AEs since the previous visit · MG-ADL will be administered by an appropriately trained assessor, preferably the same assessor throughout the study. The recall period will be the previous 7 days. The number of days since the last visit will be <7 and the recall period will be from the last visit. · Perform clinical assessments QMG, NIF, and MGC; these should be performed at approximately the same time of day by an appropriately trained assessor, preferably the same assessor throughout the study. If subjects are taking cholinesterase inhibitors, the medication must be withheld for at least 10 hours prior to QMG and MGC testing. Collect trough (pre-IP infusion) blood samples for PK, PD, and free C5 assays at Visit 3 (Week 1) only. Trough blood samples should be drawn 5-90 minutes prior to IP infusion. Ensure subjects have a Patient Safety Information Card with IP and emergency contact information Obtaining trial drug kit allocation through IXRS Administer an IP infusion over approximately 35 minutes according to the regimen described in Section 4.5, and observe the subject for 1 hour following completion of the IP infusion. Collect peak (post-IP infusion) blood samples for PK, PD, and free C5 assays only at Visit 3 (Week 1). Peak blood samples should be taken at least 60 minutes after completion of the IP infusion.
[0165] 1.4.2.1.3. Visit 6 (4 weeks) The following tests and procedures will be completed at this visit: Measure vital signs, including assessment of systolic and diastolic BP, temperature, RR, and HR Record any new medications or changes to concomitant medications Assess and record any new or change in AEs since the previous visit Administer quality of life assessment questions (MG-QOL 15, Neuro-QOL Fatigue, and EQ-5D) MG-ADL will be administered by an appropriately trained assessor, preferably the same assessor throughout the study. The recall period will be the previous 7 days. If the number of days since the last visit is <7, the recall period will be from the last visit. Conduct clinical assessments QMG, NIF, and MGC; these are performed by appropriately trained assessors, The entire study should preferably be performed by the same assessor at approximately the same time of day. If subjects are taking cholinesterase inhibitors, they must refrain from taking the medication for at least 10 hours prior to the QMG and MGC tests. Evaluate change from baseline in MGFA post-intervention status (see Table 10). · Collect blood samples for clinical laboratory tests (chemistry and hematology). · Trough blood samples for PK, PD, free C5, and HAHA assays are collected 5-90 minutes prior to IP infusion. Ensure subjects have a Patient Safety Information Card with IP and emergency contact information Obtaining trial drug kit allocation through IXRS Administer an IP infusion over approximately 35 minutes according to the regimen described in Section 4.5, and observe the subject for 1 hour following completion of the IP infusion. Peak blood samples for PK, PD, and free C5 assays will be collected at least 60 minutes after completion of the IP infusion.
[0166] 1.4.2.2. Maintenance Phase (Visit 7 [Week 6] until the end of Study Period Visit 17 [Week 26] or earlier termination of the visit) During the maintenance phase, subjects will return for IP infusions every 2 weeks (14±2 days) according to the regimen described in Section 4.5. The following tests and procedures will be completed at each visit, beginning at Visit 7 (Week 6) and continuing until the End of Study (EOS), Visit 17 (Week 26), or Early Termination (ET): Measure vital signs, including assessment of systolic and diastolic BP, temperature, RR, and HR Record any new medications or changes to concomitant medications Assess and record any new or change in AEs since the previous visit Ensure subjects have a Patient Safety Information Card with IP and emergency contact information Administer IP and observe subjects for 1 hour following completion of IP infusion. With the exception of peak blood sampling for PK / PD and free C5 assays, IP is administered following completion of other tests and procedures. At Visit 8 (Week 8), Visit 10 (Week 12), Visit 12 (Week 16), Visit 14 (Week 20), and until EOS, Visit 17 (Week 26), or ET, the following procedures will also be completed in addition to the previous 5 procedures listed for the Maintenance Phase: Administer questions to assess quality of life (MG-QOL 15, Neuro-QOL Fatigue, and EQ-5D) The MG-ADL will be administered by an appropriately trained assessor, preferably the same assessor throughout the study. The recall period will be the previous 7 days. · Conduct clinical assessments QMG, NIF, and MGC; these should be performed by appropriately trained assessors, preferably the same assessors throughout the study, at approximately the same times of day. If subjects are taking cholinesterase inhibitors, the medication must be withheld for at least 10 hours prior to QMG and MGC testing. · C-SSRS will be performed only at Visit 10 (12 weeks) and Visit 17 (26 weeks) / ET. Blood samples for the HAHA assay should be collected 5-90 minutes prior to IP injection. Obtain blood samples for clinical laboratory tests (chemistry and hematology). Obtain blood samples for AChR Ab testing and HAHA assay only at Visit 10 (Week 12) and Visit 17 (Week 26) / ET Trough blood samples for PK, PD, and free C5 assays were collected 5–90 minutes prior to IP infusion only at Visits 8, 10, 14, and 17 / ET (Weeks 8, 12, 20, and 26). Mel Collect peak blood samples for PK, PD, and free C5 assays at least 60 minutes after completion of the IP infusion only at Visits 8, 10, 14, and 17 / ET (Weeks 8, 12, 20, and 26) Weight measured only at Visit 17 (26 weeks) / ET · 12-lead RCG performed only at visit 17 (26 weeks) / ET Record MG treatment status (see Table 9) only at Visit 17 (Week 26) / ET Obtain mandatory pregnancy testing for all women of potential birth potential at Visit 17 (26 weeks) / ET - Change from baseline in MGFA post-intervention status will be assessed only at Visit 10 (Week 12) and Visit 17 (Week 26) / ET 1.4.2.3. Visits for MG crisis or clinical deterioration An evaluation visit for MG crisis or clinical deterioration must occur as soon as possible within 48 hours of the investigator's knowledge of the onset of symptoms. Further evaluation visits may be scheduled at the investigator's discretion. The following tests and procedures will be completed at this visit: Measure vital signs, including assessment of systolic and diastolic BP, temperature, RR, and HR Record any new or concomitant medications, including all treatments for MG Assess and record any new or change in AEs since the previous visit The MG-ADL will be administered by an appropriately trained assessor, preferably the same assessor throughout the study. The recall period will be the previous 7 days or from the last visit, whichever occurs first. Conduct the clinical assessments QMG, NIF, and MGC; these should be performed by appropriately trained assessors, preferably the same assessors throughout the study, at approximately the same times of day. Collect blood samples for AChR Ab testing Collect blood samples for clinical laboratory tests (chemistry and hematology) Further testing may be performed at the investigator's discretion if medically indicated for evaluation of clinical progression. PK, PD sampling at or during crisis or progression visits: If IP is not administered, collect one blood sample for PK, PD, and free C5 assays. If IP is administered at the MG Crisis Assessment Visit or Clinical Exacerbation Visit per the protocol schedule, collect two blood samples, trough and peak: [1] 5-90 minutes prior to the IP infusion and [2] at least 60 minutes after completion of the IP infusion. If a subject undergoes PE during a crisis or clinical deterioration, an additional dose of IP will be administered. Collect three blood samples for PK, PD, and free C5: [1] 5-90 minutes before PE, [2] 60 minutes after PE and before IP, and [3] at least 60 minutes after completion of the IP infusion. IP administration: Subjects will continue to receive IP dosing according to the IP dosing schedule specified in the protocol. If a crisis or clinical progression visit coincides with a routine protocol visit, the subject will receive regularly scheduled IP dosing according to the protocol schedule. If the subject receives PE, an additional dose (2 vials IP) must be administered within 60 minutes after each PE session. If the subject is scheduled to receive a protocol-scheduled dose on the day of the PE session, the scheduled dose must be administered within 60 minutes after the scheduled dose. It should be administered within 60 minutes of the end of PE.
[0167] 1.4.2.4 Scheduled outpatient visits Additional (unscheduled) visits beyond those specified are permitted at the discretion of the Investigator. Procedures, tests, and evaluations are performed at the discretion of the Investigator. If a scheduled visit is performed, any tests, procedures, or evaluations performed at the scheduled visit must be recorded in the eCRF.
[0168] 1.4.3. Safety follow-up period (post-procedure + 4 weeks)Safety follow-up period (post-procedure + 8 weeks) If a subject discontinues the study at any time during the study period after receiving any dose of IP (eculizumab or placebo) or does not wish to participate in the extension study after completion of this study, a follow-up visit for safety evaluation is required 4 weeks after the last dose of IP. The following tests and procedures will be completed at the safety follow-up visit: Measure vital signs, including assessment of systolic and diastolic BP, temperature, RR, and HR Record any new medications or changes to concomitant medications Assess and record any new or change in AEs since the previous visit Implement MG-QOL15 The MG-ADL will be administered by a properly trained assessor, preferably the same assessor throughout the study. The recall period will be the previous 7 days. Conduct clinical assessments QMG, NIF, and MGC; these should be performed at approximately the same time of day by appropriately trained assessors, preferably the same assessors throughout the trial. If subjects are taking cholinesterase inhibitors, the medication must be withheld for at least 10 hours prior to QMG and MGC testing. Evaluate change from baseline in MGFA post-intervention status (see Table 10).
[0169] [Table 13]
[0170] If a subject discontinues due to an AE, the AE will be followed until it is resolved or determined to be medically stable in the opinion of the PI.
[0171] 1.5. Number of subjects Approximately 92 subjects with refractory gMG were randomized in a 1:1 (eculizumab:placebo) ratio at approximately 100 centers. Randomization was across centers and according to MGFA clinical classification (class a vs. class b and class II and III vs. class IV) (see Table 7). ) were stratified.
[0172] 1.6. Treatment Allocation Approximately 92 subjects with refractory gMG will be randomized, 46 subjects to eculizumab and 46 subjects to placebo. All patients will remain on their assigned double-blind treatment until the EOS / ET visit. Randomized subjects who discontinue after initiation of study treatment will not be replaced. Allocation will be done via the IXRS at each visit.
[0173] 2. Subject Selection and Discontinuation 2.1. Subject Inclusion Criteria 1. Male or female subjects ≥ 18 years of age 2. The diagnosis of MG must be made by the following tests: A positive serological test for anti-AChR Ab identified at screening, and One of the following: a. A history of abnormal neuromuscular transmission testing demonstrated by single fiber electromyography (SFEMG) or repetitive nerve stimulation, or b. History of a positive anticholinesterase test, e.g., an edrophonium chloride test, or c. Subject has demonstrated improvement in MG symptoms with an oral cholinesterase inhibitor as assessed by the treating physician. 3. MGFA clinical classification class II–IV at screening. 4. MG-ADL total score must be ≥ 6 at screening and randomization (Day 1) 5. Subjects with: a. Failed treatment with two or more ISTs* (either in combination or as monotherapy) for 1 year or more, i.e., continuing to have ADL impairment despite IST (persistent weakness, experiencing crises, or being unable to tolerate IST); or b. Subjects who have failed at least one IST and require chronic plasma exchange or IVIg to control symptoms, i.e., PE or IVIg on a regular basis at least every 3 months for management of muscle weakness over the last 12 months. *Immunosuppressants include, but are not limited to, corticosteroids AZA, MMF, methotrexate (MTX), cyclosporine, tacrolimus, or cyclophosphamide. 6. If subjects entering the study are receiving AZA, they must have been on AZA for ≥ 6 months and be on a stable dose for ≥ 2 months prior to screening. 7. If subjects entering the study are receiving other IST, i.e., MMF, MTX, cyclosporine, tacrolimus, or cyclophosphamide, they must have been on IST for ≥ 3 months and on a stable dose for ≥ 1 month prior to screening. 8. If subjects entering the study are taking oral corticosteroids, they must be on a stable dose for ≥ 4 weeks (28 days) prior to screening. 9. If subjects entering the study are taking a cholinesterase inhibitor, they must be on a stable dose for ≥ 2 weeks prior to screening. 10. Female subjects of childbearing potential must have a negative pregnancy test (serum human chorionic gonadotropin [HCG]). All subjects must be on an effective, reliable, and medically approved contraceptive regimen throughout the study and for 5 months after cessation of treatment. 11. Subjects must provide written informed consent. 12. Subjects must be able and willing to comply with study procedures.
[0174] 2.2. Subject Exclusion Criteria 1. History of thymoma or other neoplasm of the thymus. 2. History of thymectomy within 12 months prior to screening. 3. Weakness affecting only the ocular or periocular muscles (MGFA Class I) 4. MG Crisis at Screening (MGFA Class V) 5. Pregnancy or breastfeeding 6. Any systemic bacterial or other infection that, in the opinion of the investigator, was clinically significant and was not treated with appropriate antibiotics. 7. Unresolved meningococcal infection 8. Use of IVIg within 4 weeks prior to randomization (Day 1) 9. Use of PE within 4 weeks prior to randomization (Day 1) 10. Use of rituximab within 6 months prior to screening 11. Participation in any other investigational drug trial or exposure to any other investigational drug, device, or procedure within 30 days prior to screening 12. Subjects who have received prior treatment with eculizumab 13. Hypersensitivity to mouse proteins or excipients of eculizumab 14. Any medical condition which, in the opinion of the Investigator, may preclude the subject's participation in the study, pose any additional risk to the subject, or confound the subject's evaluation.
[0175] 2.3. Subject Discontinuation Criteria 2.3.1. Discontinuation of a subject from a clinical trial Subjects are allowed to withdraw consent at any time. Every effort should be made to ensure that subjects are willing to comply with study participation before screening procedures are performed, and subjects should be fully informed of restrictions related to changes in concomitant medications during the study. Investigators may choose to discontinue treatment of subjects because of AEs, as well as conditions or illnesses that would prevent compliance with the protocol from the standpoint of the subject's safety or well-being. Study staff should inform the sponsor and their site monitors of any study discontinuations as soon as possible.
[0176] Reproductive and developmental studies of eculizumab have not been performed; therefore, eculizumab should not be administered to pregnant women. At the last follow-up visit, all subjects of childbearing potential must continue to use adequate contraception until 5 months after discontinuation of eculizumab treatment. If a subject becomes pregnant, IP must be discontinued immediately and the sponsor must be notified. Each pregnancy will be followed to term, and the sponsor will be informed regarding the outcome.
[0177] 2.3.2. Handling of Cancellations If a subject discontinues or is discontinued from the study, the investigator will record the reason for discontinuation. Whenever possible, all subjects who discontinue early from the study will have a full evaluation at the ET visit for safety as per the schedule of evaluations (Table 6). A follow-up visit for safety evaluations is required 8 weeks after the last dose of IP administration (Table 6).
[0178] If a subject discontinues due to an AE, the event will be followed until it is resolved or the subject is determined to be medically stable in the opinion of the PI. Every effort will be made to ensure safety follow-up procedures as specified in the protocol.
[0179] Subjects who are unable to return for final evaluation will be contacted by site study staff to bring them into compliance with the protocol. Because obtaining follow-up data on subjects who have been discontinued due to an AE or SAE is crucial, follow-up due diligence information management will consist of three telephone contacts followed by one registered mail to the subject's last known address. However, every effort should be made to address safety follow-up procedures specified in the clinical trial protocol.
[0180] 2.3.3. Sponsor Termination of a Clinical Trial Alexion Pharmaceuticals, Inc. or a regulatory agency may terminate a clinical trial at any time for any reason, including, for example, clinical or administrative reasons.
[0181] 2.3.4. Definition of End of Study The end of the study will be defined as the last visit completed by the last patient.
[0182] 3. Treatment of Subjects 3.1. Description of investigational drug Eculizumab (600 mg, 900 mg, or 1200 mg) or matching placebo will be administered intravenously over approximately 35 minutes according to the regimen shown in Table 11.
[0183] [Table 14]
[0184] Introduction Eculizumab or placebo: 3 vials IP (equivalent to 900 mg eculizumab) weekly (every 7 days ± 2 days) for 4 weeks, followed by 4 vials IP (equivalent to 1200 mg eculizumab) 1 week later for the fifth dose (Visit 6 / 4 weeks).
[0185] maintenance period Eculizumab or placebo: 4 vials IP (equivalent to 1200 mg eculizumab) every 2 weeks (14 days ± 2 days).
[0186] *Additional dose If PE is performed because of clinical progression (as defined by this protocol), an additional IP (2 vials, equivalent to 600 mg of eculizumab or matching placebo) will be administered within 60 minutes after the end of each PE session. If PE is performed on a day of regularly scheduled IP administration, subjects will receive the regularly scheduled number of vials (3 vials at Visits 2-4; 4 vials at all other visits) within 60 minutes after each PE session.
[0187] 3.2. Concomitant medications 3.2.1. Permitted Medication Applications 3.2.1.1 Symptomatic and supportive care Symptomatic and supportive care will be permitted during the course of the trial for underlying conditions.
[0188] The following medications are permitted under certain circumstances and restrictions:
[0189] Cholinesterase inhibitors For subjects enrolling in the study who have been receiving a cholinesterase inhibitor for at least 2 weeks prior to screening, the dose and schedule of their cholinesterase inhibitor will be maintained stable throughout the study unless there is a compelling medical need. Increases in cholinesterase therapy required as a result of other medical causes of current inter-disease or other exacerbations will be permitted, but dosing should be returned to dosing levels at the time of study enrollment as soon as practicable, and the study sponsor should be informed of any changes. Cholinesterase inhibitor treatment must be withheld for at least 10 hours prior to QMG and MGC testing. Reductions in cholinesterase inhibitors will be considered based on clinical evaluation, and sponsor approval must be obtained prior to any dose change in order for the subject to remain in the study. Dose increases as a result of current illness or other medical causes are permitted, but doses should be returned to dose levels at study entry as soon as practicable, and the study sponsor should be informed.
[0190] Immunosuppressants The following immunosuppressants are permitted during the trial: corticosteroids, AZA, MMF, MTX, tacrolimus, cyclosporine, or cyclophosphamide. The immunosuppressant to be used for an individual subject and its appropriate dose level are at the discretion of the treating physician. Corticosteroids - For subjects enrolling in the study receiving oral corticosteroids, e.g., prednisone, the dose / schedule must be stable for 4 weeks prior to the study and may not be changed for the entire double-blind study period. If a reduction or taper in steroid dose is considered during the study period based on clinical evaluation, sponsor approval must be obtained prior to the change in order for the subject to remain in the study. If the dose level must subsequently be increased, the dose level increase cannot exceed the dose level reported at baseline (at the start of randomized treatment). High-dose steroids may be reserved for subjects who experience Clinical Deterioration as defined by this protocol. If a subject requires rescue treatment for Clinical Deterioration, every effort should be made to notify the sponsor within 24 hours of administration. AZA, MMF, MTX, tacrolimus, cyclosporine or cyclophosphamide - For subjects enrolled in the study receiving the immunosuppressants mentioned above, the dosing regimen of the immunosuppressant may not be changed during the entire double-blind study period. If a change in dosing regimen is considered due to known toxicities or side effects associated with a given immunosuppressant, sponsor approval must be obtained prior to any dose change in order for the subject to remain in the study. A different immunosuppressant cannot be added or substituted during the 26-week double-blind study period.
[0191] 3.2.1.4. Plasma exchange / plasmapheresis (PE) / IVIg The use of PE or IVIg will be permitted for subjects who experience Clinical Deterioration as defined by this protocol. The rescue therapy used for a particular subject is at the discretion of the treating physician. If a subject requires rescue therapy, every effort should be made to notify the sponsor within 24 hours.
[0192] If PE is administered as rescue therapy, an additional IP (2 vials) will be administered within 60 minutes after the end of each PE session. Administration will continue according to the subject's specific dose-administration schedule. If the subject is scheduled to receive a protocol-scheduled dose on the day of the PE session, the scheduled dose will be administered within 60 minutes after the end of the PE session.
[0193] 3.2.2. Denied drug coverage The following concomitant medications are prohibited during the study: Use of Rituximab 3.3. Treatment Compliance IP injections to subjects will be under the supervision of the PI / Subinvestigator or their designee to ensure that subjects receive the appropriate dose at the appropriate time during the trial.
[0194] Subjects who are unable to return for a scheduled visit within the allowed interval must be contacted by site study staff to determine the reason for the missed appointment. Instructions for handling missed visits are provided in Section 1.4.2.
[0195] 3.4. Randomization and blinding Randomization Subjects will be randomized on Day 1 after the investigator confirms their eligibility. Subjects will be randomized in a 1:1 ratio to receive eculizumab infusion vs. placebo infusion. Randomization will be across centers using the IXRS. Randomization stratification will be based on MGFA clinical classification assessed at the screening visit according to the following four groupings: a. MGFA Class IIa and IIIa b. MGFA Class IVa c. MGFA classes IIb and IIIb, and d. MGFA Class IVb The MGFA clinical classification is described in Table 7.
[0196] 3.4.2. Blinding and Unblinding All study subjects, study site personnel, sponsor staff, sponsor designees, and all staff directly involved in the conduct of the study will be masked to subject treatment allocation. Double blinding will be maintained by using identical IP kits and labels for eculizumab and placebo. Placebo will have the same appearance as eculizumab. Randomization codes will be maintained by Almac Clinical Services. There is no antidote to reverse the effects of eculizumab.
[0197] Therefore, unblinding does not aid in planning patient treatment for a given event. Unblinding should only be considered for subject safety. If unblinding is deemed necessary by the investigator, the investigator may unblind the patient's treatment assignment using the IXRS. The investigator must note the date, time, and reason for unblinding.
[0198] The investigator should inform the medical monitor that the patient has been unblinded but is not required to reveal to the medical monitor the patient's treatment assignment.
[0199] If the AE is an unexpected related serious AE, it will be unblinded by the sponsor for that particular subject only. Blinding will be maintained only for those responsible for the ongoing conduct of the study (e.g., administrative, monitoring investigators, etc.) and those responsible for data analysis and interpretation of the results at the end of the study, e.g., biometric personnel. Unblinded information will be It is only accessible to those who need to be involved in safety reporting to health authorities, ethics committees and / or IRBs.
[0200] Investigators will receive only blinded information unless unblinded information is deemed necessary for safety reasons.
[0201] 4. Investigational Drug Materials and Management 4.1. Investigational Drug Each vial of IP contains 300 mg of eculizumab or matching placebo for IV administration.
[0202] 4.2. Investigational Product Packaging and Labeling The active IP, eculizumab, is manufactured and supplied by Alexion as a solution at a concentration of 10 mg / ml in a single 30 mL vial. The comparator is manufactured by Alexion Pharmaceuticals, Inc. as a compatible sterile, clear, colorless solution in an identical 30 mL vial containing the same buffer components but no active ingredients. See Table 12.
[0203] All study medications will be manufactured in vials, packaged in kits, and labeled in the same manner.
[0204] The IP vials will be individually packaged into kits. Both the vials and the kits will be labeled according to the protocol and local regulatory requirements. Each kit will have a label describing the contents and a place for the pharmacist to record the subject number and initials.
[0205] Study medication will be shipped and opened to each participating investigational site once all required paperwork required by federal, state, and local regulations has been received (Table 12).
[0206] [Table 15]
[0207] 4.3. Investigational Drug Storage An IP will be issued to a facility once all necessary required documentation based on Federal, State, and local regulations has been received. See Table 12.
[0208] Upon arrival at the facility, the IP should be immediately removed from the shipping cooler and stored under refrigerated conditions at 2-8°C. The pharmacist should immediately document receipt of the IP and notify the distributor if the vial is damaged and / or if a temperature excursion occurs during shipping. IP should be stored in a secure, limited-access storage area and the temperature should be monitored daily.
[0209] Dilute solutions of IP may be stored at 2-8°C (36-46°F) for up to 24 hours before administration. If the IP is prepared more than 4 hours prior to the subject's visit, the diluted material should be stored at 2-8°C. The solution should be allowed to warm to room temperature prior to administration. The material should not be heated to anything other than ambient temperature (e.g., by microwave or other heat source).
[0210] 4.4. Investigational Product Manufacturing IP infusions are manufactured using sterile technique. Each vial of IP contains 300 mg of active ingredient or matching placebo in 30 mL of drug solution.
[0211] Withdraw the required amount of IP from the vial. Transfer the recommended dose to an infusion bag. Dilute the IP to a final concentration of 5 mg / mL by adding the appropriate amount (equal volume) of 0.9% Sodium Chloride Injection, USP; 0.45% Sodium Chloride Injection, USP; 5% Dextrose in Water Injection, USP; or Ringer's Injection, USP to the infusion bag. The final volume of the 5 mg / mL diluted IP solution is 120 mL for the 600 mg dose (2 vials), 180 mL for the 900 mg dose (3 vials), and 240 mL for the 1200 mg dose (4 vials), as shown in Table 13.
[0212] [Table 16]
[0213] Ejaculation Gently invert the infusion bag containing the diluted IP solution to ensure thorough mixing of drug and diluent. Since the investigational drug does not contain a preservative, discard any unused portion of the vial. The diluted solution should be allowed to warm to room temperature by exposure to ambient air prior to administration.
[0214] Administration Do not administer as an IV push or bolus injection IP is administered only via IV infusion and must be diluted to a final concentration of 5 mg / mL prior to administration. Prior to administration, the diluted solution, if refrigerated, is warmed to room temperature by exposure to ambient air. The diluted solution should not be heated in a microwave or with any heat source other than ambient air temperature. Parenteral drugs are visually inspected for particulate matter and discoloration prior to administration.
[0215] The diluted IP is administered intravenously over 35 minutes (range 25-45 minutes). There is no need to protect the infusion bag from light while the IP is being administered to the subject. At the institution's discretion, the diluted IP may be administered by gravity feed, syringe-type pump, or infusion pump. Subjects are monitored for 1 hour after infusion.
[0216] If an AE occurs during administration of the IP, the infusion may be slowed or stopped depending on the nature and severity of the event at the investigator's discretion. The total duration of the infusion should not exceed 2 hours. AEs must be recorded in the subject's source documents and CRF.
[0217] 5. Evaluation of efficacy The treatment period begins with the first infusion of IP (eculizumab or placebo). The 26-week study period defines the period for evaluation of study endpoints (specified in Table 6, Evaluation Schedule). Efficacy is evaluated by comparing eculizumab outcomes to placebo outcomes. Statistical analyses of efficacy endpoints are summarized below and described in more detail in the Statistical Analysis Plan. For all scales presented below, except for the EQ Visual Analog Scale (VAS) and the Myasthenia Gravis Foundation of America (MGFA) Post-Intervention Status (PIS), higher scores indicate greater functional impairment.
[0218] 5.1. MG Activities of Daily Living Profile (MG-ADL) The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living (ADL) in MG subjects (see Table 1). The 8 items of the MG-ADL were derived from the symptom-based component of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) dysfunction related to MG-derived effects. In this functional status instrument, each response is graded from 0 (normal) to 3 (most severe). The range of the total MG-ADL score is 0-24. A clinically meaningful improvement in a patient's MG-ADL would be a 3-point or greater reduction in score after 26 weeks of treatment. The recall period for the MG-ADL is the previous 7 days. The MG-ADL will be administered by appropriately trained assessors at Screening, Day 1, Weeks 1-4, 8, 10, 12, 16, 20, and 26 or ET (Visits 2-6, 8, 10, 12, 14, and 17, or ET), preferably the same assessors throughout the study.
[0219] 5.2. QMG Scoring System The current QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item); each graded from 0 to 3, with 3 being the most severe (see Table 2). The total QMG score ranges from 0 to 39. The QMG scoring system is considered to be an objective evaluation of the treatment of MG and is based on quantitative testing of index muscle groups. The MGFA task force recommended that the QMG score be used in prospective studies of the treatment of MG (15). A clinically meaningful improvement in a patient's QMG would be a 4-point or greater reduction in the score after 26 weeks of treatment. QMG is performed at screening, days 1, weeks 1 to 4, 8, 12, 16, 20, and 26 or ET (Visits 1 to 6, 8, 10, 12, 14, and 17 or ET).
[0220] 5.3. MGC Score The MGC is a validated assessment tool for measuring the clinical status of subjects with MG (16). The MGC assesses 10 important functional domains most frequently affected by MG, and the scale is weighted for clinical significance incorporating subject-reported outcomes (see Table 3). A clinically meaningful improvement in a patient's MGC would be a 3-point or greater reduction in score after 26 weeks of treatment. The MGC is administered at Screening, Day 1, Weeks 1-4, 8, 12, 16, 20, and 26 or ET (Visits 1-6, 8, 10, 12, 14, and 17 or ET).
[0221] 5.4. Quality of life assessment MG-QOL 15 The 15-item Myasthenia Gravis Quality of Life Scale (MG-QOL 15) (see Figure 1) is a health-related quality of life assessment instrument specific to subjects with MG. The MG-QOL 15 was designed to provide information about the subject's perception of impairment and disability, and the degree to which disease symptoms are tolerated, and to be easy to administer and interpret (17). The MG-QOL 15 is completed in full by the subject. Higher scores indicate a higher degree of impairment and disability. It indicates dissatisfaction with MG-related dysfunction. A clinically meaningful improvement in a patient's MG-QOL 15 would be an increase in score after 26 weeks of treatment. The MG-QOL 15 is administered at Screening, Day 1, Weeks 4, 8, 12, 16, 20, and 26 or ET (Visits 1-2, 6, 8, 10, 12, 14, and 17 or ET).
[0222] Neuro-QOL fatigue Neuro-QOL Fatigue is a reliable and valid short 19-item fatigue test completed by the subject (18). Higher scores indicate greater fatigue and greater impact of MG on activity (see Table 5). A clinically meaningful improvement in a patient's Neuro-QQL would be reflected by a reduction in score after 26 weeks of treatment. Neuro-QOL Fatigue is administered at Day 1, Weeks 4, 8, 12, 16, 20, and 26 or ET (Visits 2, 6, 8, 10, 12, 14, and 17 or ET).
[0223] EUROQOL (EQ-5D) The EUROQOL (EQ-5D) is a reliable and valid test of health status completed by subjects in five domains: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression (19). Each domain has three levels: level 1 (no problems), level 2 (some problems), and level 3 (very problems) (see Figures 2A and 2B). The EQ VAS records the subject's self-assessed health on a vertical 20 cm visual analog scale, where the endpoints are labeled "best imaginable health state" marked with "100" and "worst imaginable health state" marked with "0". A clinically meaningful improvement in a patient's EQ-5D would be reflected as an increase in score after 26 weeks of treatment. EQ-5D will be administered at Day 1, Weeks 4, 8, 12, 16, 20, and 26 or ET (Visits 2, 6, 8, 10, 12, 14, and 17 or ET).
[0224] 5.5. Other Efficacy Assessments 5.5.1. Negative Inspiratory Flow (NIF) and Forced Vital Capacity Subjects with increasing severity of MG may suffer from potentially fatal respiratory complications, including profound respiratory muscle weakness. Respiratory function is closely monitored for evidence of respiratory failure in MG subjects, and ventilatory support is recommended in the event of consistent decline in graded measurements of forced vital capacity (FVC) or negative inspiratory flow (NIF), loss of upper airway integrity (difficulty handling oral secretions, swallowing, or speaking), or in the setting of emerging respiratory failure. FVC, as one of the test items of QMG, is performed when QMG is performed. NIF was performed using a NIF meter. It is measured at Screening, Day 1, Weeks 1-4, 8, 12, 16, 20, and 26 or ET (Visits 1-6, 8, 10, 12, 14, and 17 or ET).
[0225] 5.5.2. Post-MGFA intervention state MG clinical status was assessed using the MGFA Post-Intervention Status. See Table 10. Status change categories of improved, unchanged, worse, exacerbation, and death due to MG, as well as minor symptoms (MM), will be assessed and recorded at Weeks 4, 12, and 26 ET (Visits 6, 10, and 17 or ET) by the PI or the same neurologist experienced in evaluating MG subjects throughout the study. MM subscores, i.e., MM-0, MM-1, and MM-3, will not be used in this protocol.
[0226] 6.2. Determining sample size The study design is randomized, double-blind, placebo-controlled. Subjects will be randomly assigned 1:1 to receive eculizumab or placebo. The randomization stratification variable will follow the Myasthenia Gravis Foundation of America (MGFA) clinical classification of MG into four groups: (Classes IIa and IIIa, Class IVa, Classes IIb and IIIb and Class IVb).
[0227] The sample size and power calculation process is as follows: 1:1 randomization (eculizumab:placebo) Power of 90% for both the primary and first secondary endpoints Two-sided 5% level of significance Drop-out rate: 15% For both endpoints, the mean change from baseline for MG-ADL is assumed to be 4 for eculizumab and 1.5 for placebo with a standard deviation of 3.25, the mean change in QMG total score is assumed to be 7 for eculizumab and 3 for placebo with a standard deviation of 6, and the mean ranked difference between treatment groups is assumed to be 3. Sample size calculations were based on t-tests.
[0228] Using these assumptions, approximately 92 subjects (46 eculizumab and 46 placebo) would yield 90% power to detect a treatment difference at 26 weeks.
[0229] 6.3. Analysis population Analyses will be performed during the double-blind study period to compare the eculizumab and placebo groups. Analyses will include efficacy, safety, and PK / PD analyses.
[0230] 6.3.1. Full analysis set The Full Analysis Set (FAS) is the population in which the primary, secondary, and tertiary efficacy analyses will be performed and consists of all subjects randomized to IP and who received at least one dose of IP (eculizumab or placebo treatment) and who have at least one post-IP infusion efficacy assessment. Subjects will be compared for efficacy according to the treatment they were randomly assigned to receive, regardless of the treatment they actually received.
[0231] 6.3.2. Per Protocol Population The per protocol (PP) set is a subset of the Full Analysis Set (FAS) population excluding subjects with major protocol deviations. The possible categories of major protocol deviations are specified in the statistical analysis plan. The per protocol set is: There were no major protocol deviations or deviations from inclusion / exclusion criteria that could have affected efficacy; Subjects who received at least 80% of the required dose and participated in the study for 26 weeks or who received at least 80% of the required dose until the time of discontinuation due to clinical progression (e.g., MG crisis / exacerbation) This includes all subjects. The PP population was fully described in the statistical analysis plan, and subjects were identified prior to database lock. Efficacy analyses will also be performed on the PP data set.
[0232] 6.7. Efficacy Analysis NOTE: For the study period, baseline is defined as the last available assessment prior to treatment for all subjects, regardless of treatment group.
[0233] 6.7.1. Primary efficacy endpoint The primary efficacy outcome measure was baseline MG-ADL score at 26 weeks of the study. The primary efficacy analysis will be performed on the available 26-week data from the study period for all subjects. If a statistically significant difference (p≦0.05) between the eculizumab treatment group and the placebo group is observed for the change from baseline in MG-ADL total score at week 26, the trial will be considered to have met its primary efficacy objective. Confidence intervals and p-values are presented. For the primary analysis of the change from baseline in MG-ADL total score at week 26, the treatment groups will be compared to the effect of treatment using a worst-ranked score analysis (i.e., analysis of covariance [ANCOVA] with ranks). The baseline MG-ADL total score and the randomization stratification variable should also be covariates in the model. In this analysis, the actual change from baseline will be ranked from highest (best improvement in MG-ADL score) to lowest (least improvement / greatest deterioration in MG-ADL score) across all subjects who did not require rescue treatment. Subjects who required rescue treatment will then be given a lower rank. These lower ranks are based on the time from start of study drug (Day 1) to rescue treatment. Subjects with the shortest time to rescue treatment are given the absolute lowest rank in the analysis, and subjects with the longest time to rescue treatment are given one rank lower than the lowest ranked subject with no rescue treatment. The last observation carried forward method was used for missing changes from baseline at week 26 for patients who did not require rescue treatment and were missing week 26.
[0234] A sensitivity analysis for the actual change from baseline in MG-ADL total score at week 26 was also performed. Treatment groups were compared to the treatment effect using the actual change from baseline in MG-ADL total score at week 26 using ANCOVA analysis. The baseline MG-ADL total score and the randomization stratification variable are also covariates in the model. The last observation carried forward method is used for missing changes from baseline at week 26.
[0235] A sensitivity analysis was also performed for the actual change from baseline in the MG-ADL total score at week 26. In the sensitivity analysis, a repeated measures model is used to compare treatment groups with treatment effects and visits. The baseline MG-ADL total score, the randomization stratification variable, and an indicator of the subject's IST treatment status are also covariates in this model. Subjects have an IST treatment status variable defined based on the IST treatment they receive.
[0236] Additionally, summaries of change from baseline in MG-ADL total score at Week 26 will be generated by treatment group for subjects who failed IST. Subjects who have failed treatment for 1 year or more with two or more ISTs, either sequentially or in combination. Patients who have failed at least one IST and require chronic plasma exchange or IVIg to control symptoms.
[0237] 6.7.2. Secondary Efficacy Analyses Unless otherwise specified, secondary efficacy analyses will use available 26-week data from the study period. Hypothesis testing for the secondary efficacy analyses comparing eculizumab treatment with placebo treatment will be performed using a closed procedure with the following rank order: 1. Change from baseline in QMG total score at week 26 2. Proportion of subjects with at least a 3-point reduction in MG-ADL total score from baseline to Week 26 and no rescue therapy 3. Proportion of subjects with at least a 5-point reduction in QMG total score from baseline to Week 26 and no rescue therapy 4. Change from baseline in MGC score at week 26 5. Change from baseline in MG-QOL15 at Week 26 Hypothesis testing proceeded from the highest ranked change from baseline in QMG total score (#1) to the change from baseline in MG-QOL-15 (#5) at week 26. and if statistical significance is not achieved for an endpoint (p≦0.05), lower ranked endpoints are not considered statistically significant. Confidence intervals and p-values are presented for all secondary efficacy endpoints for descriptive purposes, despite being closed procedure outcomes.
[0238] Secondary endpoints, including changes from baseline, will be analyzed using worst-case ranked analysis of covariance (ANCOVA) as described for the primary efficacy endpoint as the primary analysis for the specific secondary endpoint. Ranked ANCOVA will have effects for treatment, baseline for the specific endpoint, and randomization stratification variables.
[0239] A sensitivity analysis for the change from baseline in QMG at week 26 is analyzed using a repeated measures model with effects for treatment, visits, and baseline QMG score to compare treatment groups. The randomization stratification variable is also a covariate in this model. A sensitivity analysis for the actual change from baseline in QMG score at week 26 is also performed. Treatment groups are compared to the treatment effect using an ANCOVA analysis with the actual change from baseline in WMG score at week 26. The baseline QMG score and the randomization stratification variable are also covariates in this model. Last observation carried forward is used for the missing change from baseline at week 26.
[0240] Sensitivity analyses for the change from baseline in MGC at Week 26 will be analyzed using a repeated measures model with effects for treatment, visits, and baseline MGC score to compare treatment groups. The randomization stratification variable is also a covariate in the model.
[0241] Sensitivity analyses for the change from baseline in MG-QOL-15 at Week 26 will be analyzed using a repeated measures model with effects for treatment, visits, and baseline MG-QOL-15 scores to compare treatment groups. The randomization stratification variable is a covariate in the model.
[0242] The proportion of subjects with at least a 3-point reduction in MG-ADL total score from baseline to week 26 and no rescue therapy will be analyzed by the Cochran-Mantel-Haenszel test stratified by the randomization stratification variable to compare eculizumab versus placebo.
[0243] The proportion of subjects with at least a 5-point reduction in QMG total score from baseline to week 26 and no rescue therapy will be analyzed by the Cochran-Mantel-Haenszel test stratified by the randomization stratification variable to compare eculizumab versus placebo.
[0244] Further sensitivity analyses are performed to evaluate the impact of IST treatment status on various secondary endpoints. Sensitivity analyses for the change from baseline in the secondary endpoints (i.e., QMG, MGC, and MG-QOL-15) at Week 26 are analyzed using a repeated measures model with effects for treatment, visits, and baseline scores to compare treatment groups. The randomization stratification variables and an indicator of the subject's IST treatment status are also covariates in this model. Subjects have an IST treatment status variable defined based on the IST treatment they received.
[0245] Additionally, a summary of changes from baseline in QMG, MGC, and MG-QOL-15 at Week 26 will be provided by treatment group for subjects who failed IST. Two or more ISTs used consecutively or in combination for one or more years Subjects who have failed the procedure Subjects who have failed at least one IST and require chronic plasma exchange or IVIg to control symptoms.
[0246] 6.7.3. Tertiary efficacy endpoints Tertiary efficacy analyses during the study period included: 1. Response time as measured by reduction in MG-ADL total score (reduction of 3 points from baseline) 2. Change from baseline in Neuro-QOL fatigue at week 26 3. Change from baseline in EQ-5D at week 26 4. Change from baseline in NIF at Week 26 in subjects with above baseline NIF 5. Change from baseline in FVC at Week 26 in subjects with abnormal FVC at baseline 6. Change from baseline in individual MG-ADL items and change from baseline in the Bulbar (items 1, 2, and 3), Respiratory (item 4), Limb (items 5 and 6), and Ocular (items 7 and 8) MG-ADL subcategories at Week 26 in subjects with abnormal baseline scores for the specific item or subcategory 7. Change from baseline in MGFA post-intervention status at week 26.
[0247] Treatment groups are compared for response time to MG-ADL total score (reduction in MG-ADL 3 points from baseline) using Cox PH regression with robust variance estimation. The randomization stratification variable is also a covariate in the model. Estimates are based on Wald tests of log hazard ratios.
[0248] Quality of life was summarized into quality of life instruments where appropriate, and treatment group comparisons were made as specified in the Statistical Analysis Plan (SAP).
[0249] Tertiary endpoints, including changes from baseline, will be analyzed using worst-case ranked ANCOVA as described for the primary efficacy endpoint as the primary analysis for the specific tertiary endpoint. Ranked ANCOVA will have effects for treatment, baseline for the specific endpoint, and randomization stratification variables.
[0250] Sensitivity analyses for the change from baseline in NIF at week 26 for subjects with abnormal NIF at baseline were analyzed using a repeated measures model with effects for treatment, visit, and baseline NIF to compare treatment groups. The randomization stratification variable was also a covariate in the model.
[0251] Sensitivity analyses for the change from baseline in FVC are analyzed using a repeated measures model with effects for treatment, visit, and baseline FVC to compare treatment groups. The randomization stratification variable is also a covariate in the model.
[0252] Sensitivity analyses of the change from baseline in the individual MG-ADL items and subcategories at Week 26 in subjects with abnormal baseline will be analyzed using a repeated measures model with effects for treatment, visits, and baseline, and baseline MG-ADL individual items and subcategories as specified for the analysis, to compare treatment groups. The randomization stratification variable is also a covariate in the model. In addition, sensitivity analyses of the change from baseline in the individual MG-ADL items and subcategories at Week 26 for all Full Analysis Set (FAS) and all PP subjects will be analyzed using a repeated measures model with effects for treatment, visits, and baseline MG-ADL individual items and subcategories as specified for the analysis. Repeated measures models were used to compare treatment groups using item or subcategory scores of MG-ADL. The randomization stratification variable was also a covariate in this model. Finally, similar sensitivity analyses and / or summaries were made in the subset of subjects who were normal at baseline and became abnormal after baseline in the individual MG-ADL items and subcategories (depending on the number of subjects).
[0253] A summary of subjects who went from normal to abnormal for NIF and FVC is shown. A summary of subjects who went from normal to abnormal for specific MG-ADL individual item subcategories is shown.
[0254] 6.11. Other statistical issues 6.11.1. Significance levels For all analyses, eculizumab treatment groups were compared to placebo groups, and unless otherwise specified, all hypothesis tests were two-sided with a significance level of 0.05. Estimates of treatment effects on efficacy parameters are accompanied by two-sided 95% confidence intervals for effect sizes.
[0255] 6.11.2. Missing or Invalid Data For efficacy and safety analyses, missing post-baseline efficacy and safety data will not be imputed unless presented in the analyses described in the SAP.
[0256] Interim Analysis No interim analyses are planned for this trial.
[0257] Example 2: Extension Study Described herein is an extension study conducted to evaluate the long-term safety of eculizumab in subjects with refractory gMG. Other secondary objectives include: Assessment of long-term efficacy as measured by MG-ADL Assessment of long-term efficacy with further efficacy measures including: MG, MGC, Individual items and subcategories of MG-ADL Quality of life Describe the PK and PD of eculizumab in patients with refractory gMG.
[0258] The extension study will last for 4 years (FPFV-LPLV). The first visit will occur within 2 weeks of visit 17 (week 26) in the study described above. To maintain the blinding of the previous study, all subjects will undergo a concealed run-in phase followed by an open-label maintenance phase, which is summarized in Figures 6 and 7. At selected visits, "home infusions" will be performed according to regulations and with the investigator's permission. Evaluations, treatments, and concomitant / prohibited medications will be as in the study described above.
[0259] Inclusion criteria for the extension study were completion of the previous trial. Exclusion criteria were withdrawal from the previous trial and pregnancy or intention to become pregnant. IST treatment could be changed at the discretion of the treating physician, but rituximab was prohibited.
[0260] Efficacy was measured by MG-ADL, QMG, MGC, NIF, FVC, QOL, G-QOL15, Neuro-QOL fatigue, EQ-5D and MGFA post-intervention status.
[0261] Example 3: Results from the REGAIN Study, Including the ECU-MG-301 26-Week (301) Study and the ECU-MG-302 Extension (302) Study The REGAIN study is a randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of eculizumab in patients with refractory gMG. The study enrolled and treated 125 adult patients across North and South America, Europe, and Asia. Patients were identified. All patients had a confirmed diagnosis of MG and positive serology for anti-AChR antibodies. All patients had previously failed treatment with at least two immunosuppressants or had failed treatment with at least one immunosuppressant and required chronic plasma exchange or IVIg, and had an MG-ADL total score ≥ 6 at the time of study entry.
[0262] As discussed above, patients were initially randomly assigned to one of four groups according to the MGFA clinical classification shown in Table 7: MGFA IIa / IIIa MGFA IIb / IIIB MGFA IVa MGFA IVb
[0263] The summary of MGFA classification at screening was as follows: class IIa, 25 patients in total; class IIb, 22 patients in total; class IIIa, 36 patients in total; class IIIb, 30 patients in total; class IVa, 6 patients in total; and class IVb. A total of 6 patients.
[0264] Patients were assigned to the placebo group as follows: class IIa, 15 patients (23.8%) in total; class IIb, 14 patients (22.2%) in total; class IIIa, 16 patients (25.4%) in total; class IIIb, 13 patients (20.6%) in total; class IVa, 2 patients (3.2%) in total; and class IVb, 3 patients (4.8%) in total.
[0265] Patients were assigned to the eculizumab group as follows: class IIa, 10 (16.1%) patients in total; class IIb, 8 (12.9%) patients in total; class IIIa, 20 (32.3%) patients in total; class IIIb, 17 (27.4%) patients in total; class IVa, 4 (6.5%) patients in total; and class IVb, 3 (4.8%) patients in total.
[0266] The disposition of patients who completed Study 301 and enrolled in Study 302 is shown in Table 14 below.
[0267] [Table 17]
[0268] Thus, 96.8% of placebo patients and 88.9% of eculizumab patients progressed to the extension study.
[0269] The demographics of Study 301 participants are shown in Table 15 below.
[0270] [Table 18]
[0271] The protocol defines clinical progression as a subject having one of the following: 1. MG Crease 2. Significant symptomatic worsening, defined as deterioration in any one of the individual components of the MG-ADL excluding ocular (i.e., speaking, chewing, swallowing, breathing, and leg weakness): - deterioration to grade 3, - 2-point deterioration in MG-ADL 3. The treating physician believes that the subject's health would be endangered if rescue treatment is not administered.
[0272] Rescue Therapy is defined in the protocol as follows: The use of PE or IVIg will be permitted for subjects who experience Clinical Deterioration as defined by this protocol. The rescue therapy used for a particular subject is at the discretion of the treating physician.
[0273] If PE is administered as rescue treatment, an additional IP (2 vials) will be administered within 60 minutes of the end of each PE session. Routine (per protocol schedule) IP administration will continue according to the subject's specific dose administration schedule. If the subject is scheduled to receive a protocol-scheduled dose on the day of a PE session, the scheduled dose will be administered within 60 minutes of the end of the PE session.
[0274] The total number of patients who experienced clinical progression during the protocol is shown in Table 16 below.
[0275] [Table 19]
[0276] Clinical progression requiring rescue therapy is shown below in Table 17:
[0277] [Table 20]
[0278] The primary and secondary endpoints listed above were used as follows: Primary endpoint: - Change from baseline in MG-ADL total score at week 26 Secondary endpoints (hierarchical): - Change from baseline in QMG total score at week 26 - Proportion of subjects with a ≥ 3 point reduction in MG-ADL total score from baseline to Week 26 and no rescue therapy - Proportion of subjects with a ≥ 5 point reduction in QMG total score from baseline to week 26 and no rescue therapy - Change from baseline in Myasthenia Gravis Composite (MGC) total score at week 26 - Change from baseline in MG-QoL15 at week 26
[0279] One primary endpoint was the MG-ADL score at week 26. Scores ranged from 0 to 24 and included three bulbar items, one respiratory item, two gross motor or limb items, and two ocular items. A clinically meaningful improvement in MG-ADL was defined as a reduction of 3 points or more. See Table 1.
[0280] [Table 21]
[0281] Results from patients who completed the entire protocol are shown in Table 18. Thus, the eculizumab group showed a median decrease in MG-ADL of -4 points, as shown in Table 20. This result demonstrates that eculizumab produced clinically meaningful improvements in patients with MG as measured by their MG-ADL scores.
[0282] The data was analyzed in multiple ways for statistical purposes, as shown in Tables 18, 19, 20, and 21, and in each case the eculizumab group produced a clinically meaningful improvement in MG-ADL, and the placebo group failed to produce a clinically meaningful improvement in MG-ADL. See Tables 18-21.
[0283] [Table 22]
[0284] Refractory gMG is an extremely rare subset of MG-MD, a debilitating, complement-mediated neuromuscular disease, in which patients undergo conventional treatments that are exhausting and leave them suffering from severe muscle weakness throughout the body resulting in slurred speech, inability to swallow and choking, double vision, weakness of the upper and lower extremities, disabling fatigue, shortness of breath due to respiratory muscle weakness, and episodes of respiratory failure. In the study, the primary efficacy endpoint, change from baseline at week 26 in the patient-reported assessment of Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score, did not reach statistical significance as measured by worst-case ranking analysis (p=0.0698).
[0285] [Table 23]
[0286] [Table 24]
[0287] The QMG score was then assessed for all study participants. The current QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item) and respiratory (1 item); each graded 0 to 3, with 3 being the most severe (see Table 2). The total QMG score ranges from 0 to 39. The QMG scoring system is considered an objective evaluation of treatment for MG and is based on quantitative testing of index muscle groups. The MGFA Task Force has recommended that the QMG score be used in prospective studies of treatment for MG. A clinically meaningful improvement in a patient's QMG would be a 5-point or greater reduction in score after 26 weeks of treatment.
[0288] The QMG score for the full data set was -5 for the eculizumab treatment group, thus resulting in a clinically meaningful improvement for all patients who did not require rescue and did not drop out of the study. See Table 22 below and Figure 11 for the results.
[0289] [Table 25]
[0290] MGC scores were then assessed for all study participants over time. The MGC is a validated assessment tool for measuring the clinical status of subjects with MG (16). The MGC assesses 10 important functional domains most frequently affected by MG, and the scale is weighted for clinical significance incorporating subject-reported outcomes (see Table 3). The MGC is administered at Screening, Day 1, Weeks 1-4, 8, 12, 16, 20, and 26 or ET (Visits 1-6, 8, 10, 12, 14, and 17 or ET). Total scores range from 0 to 50. A clinically meaningful improvement in a patient's MGC would be a 3-point or greater reduction in score after 26 weeks of treatment.
[0291] [Table 26]
[0292] The MGC score for the full data set was (-10) in the eculizumab treatment group, thus resulting in a clinically meaningful improvement for all patients who did not require rescue or drop out of the study. See Table 23 above for results.
[0293] The 15-item Myasthenia Gravis Quality of Life Scale (MG-QOL 15) is a health-related quality of life assessable instrument specific to subjects with MG. See Table 4. The MG-QOL 15 was designed to provide information about subjects' perceptions of impairment and disability and the degree to which disease symptoms are tolerated, and to be easy to administer and interpret. A score of 15 is completed by the subject. Total scores range from 0 to 60, with higher scores indicating a greater degree of MG-related dysfunction and dissatisfaction. A clinically meaningful improvement in OL would be a reduction in score after 26 weeks of treatment.
[0294] The MG-QOL15 median score for the full data set was (-11.5) for the eculizumab treatment group, thus resulting in a clinically meaningful improvement for all patients who did not require rescue or drop out of the study. See Table 24 for results.
[0295] [Table 27]
[0296] The Neuro-QOL Fatigue is a reliable and validated short 19-item fatigue test completed by the subject. Higher scores indicate greater fatigue and greater impact of MG on performance (see Table 5). A clinically meaningful improvement in a patient's Neuro-QQL fatigue score would be reflected by a reduction in score after 26 weeks of treatment.
[0297] As shown in Table 25 below, the eculizumab treatment group achieved clinically meaningful improvements in their Neuro-QOL fatigue scores after 26 weeks of treatment.
[0298] [Table 28]
[0299] Consideration of the significance of the REGAIN trial The first predefined secondary efficacy endpoint of change from baseline in quantitative myasthenia gravis (QMG) total score, a physician-administered assessment of MG clinical severity, achieved a p-value of 0.0129 with eculizumab treatment compared to placebo at week 26 as measured by worst-case ranked analysis. Additionally, the second and third predefined secondary efficacy endpoints of MG-ADL and responder status on the QMG achieved p-values of <0.05: The proportion of patients with at least a 3-point reduction in G-ADL total score and no rescue therapy from baseline to week 26 with eculizumab treatment achieved a p-value of 0.0229 compared to placebo, and the proportion of patients with at least a 5-point reduction in QMG total score and no rescue therapy from baseline to week 26 with eculizumab treatment achieved a p-value of 0.0018 compared to placebo.
[0300] It is encouraging that the REGAIN trial achieved clinically meaningful improvements in MG-ADL and QMG measures in patients treated with eculizumab compared to placebo. The magnitude of effect on QMG observed in this large prospective registry study is unprecedented in more than 30 years of clinical investigation of refractory MG patients. There is an urgent need in the MG community for a treatment that has the potential to dramatically improve the lifespan of patients with refractory gMG who continue to experience severe complement-mediated muscle weakness that makes it difficult or impossible to perform simple daily activities, including walking, talking, swallowing, and even breathing normally.
[0301] Prespecified sensitivity analyses were predefined to validate the results for the primary and first secondary endpoints. Three of the four predefined MG-ADL sensitivity analyses achieved p-values <0.05, including the sensitivity analysis around the primary endpoint of change from baseline in MG-ADL using repeated measures, which showed a mean change of -4.2 with eculizumab treatment at week 26 versus -2.3 with placebo at week 26, and achieved a p-value of 0.0058. Additionally, all four predefined QMG sensitivity analyses achieved p-values <0.05, including the sensitivity analysis around the first secondary endpoint of change from baseline in QMG using repeated measures, which showed a mean change of -4.6 with eculizumab treatment at week 26 versus -1.6 with placebo at week 26, and achieved a p-value of 0.0006.
[0302] Findings from this study highlight the pivotal role of complement inhibition in addressing the underlying pathophysiology of refractory gMG. Importantly, the overall data, including the first three secondary endpoints and a series of predefined sensitivity analyses, demonstrate early and sustained substantial improvements out to 26 weeks for patients treated with eculizumab compared to placebo.
[0303] Example 4: Anti-C5 Antibodies for Use in Treating Refractory Myasthenia Gravis Table 27 below includes sequences of anti-complement protein C5 specific humanized antibodies that may be used in treating refractory MG. The antibodies were anti-C5 antibodies such as eculizumab, with three heavy chain complementarity determining regions (CDRs) shown in Table 27 using the Kabat definition of CDRs as heavy chain CDR1 in SEQ ID NO: 1, heavy chain CDR2 in SEQ ID NO: 2, and heavy chain CDR3 in SEQ ID NO: 3. The eculizumab light chain CDRs are shown below as light chain CDR1 in SEQ ID NO: 4, light chain CDR2 in SEQ ID NO: 5, and light chain CDR3 in SEQ ID NO: 6. The heavy chain variable region of eculizumab is shown in SEQ ID NO: 7, and the light chain variable region of eculizumab is shown in SEQ ID NO: 8. The complete heavy chain of eculizumab is shown below as SEQ ID NO: 10, and the light chain is shown below as SEQ ID NO: 11.
[0304] The antibody may be known as BNJ441 and may be an eculizumab variant with selected mutations in the CDR regions combined with mutations in the Fc region to increase the T1 / 2 of the antibody in patients. The BNJ441 antibody has a heavy chain variable region as set forth in SEQ ID NO: 12, and the light chain variable region of BNJ441 is set forth in SEQ ID NO: 8. The complete heavy chain of BNJ441 is set forth below as SEQ ID NO: 14, and the light chain is set forth below as SEQ ID NO: 11.
[0305] The antibody can be an anti-C5 antibody unrelated to eculizumab, such as the 7086 antibody, and has three heavy chain complementarity determining regions as shown in Table 27 using the Kabat definitions of CDRs. (CDRs) as heavy chain CDR1 in SEQ ID NO: 21, heavy chain CDR2 in SEQ ID NO: 22, and heavy chain CDR3 in SEQ ID NO: 23. The 7086 antibody light chain CDRs are set forth below as light chain CDR1 in SEQ ID NO: 24, light chain CDR2 in SEQ ID NO: 25, and light chain CDR3 in SEQ ID NO: 26. The heavy chain variable region of 7086 is set forth in SEQ ID NO: 27, and the light chain variable region of 7086 is set forth in SEQ ID NO: 28.
[0306] The antibody may be an anti-C5 antibody unrelated to eculizumab, such as the 8110 antibody, and may have three heavy chain complementarity determining regions (CDRs) as shown in Table 27 using the Kabat definitions of CDRs, as heavy chain CDR1 in SEQ ID NO:29, heavy chain CDR2 in SEQ ID NO:30, and heavy chain CDR3 in SEQ ID NO:31. The 7086 antibody light chain CDRs are shown below as light chain CDR1 in SEQ ID NO:32, light chain CDR2 in SEQ ID NO:33, and light chain CDR3 in SEQ ID NO:34. The heavy chain variable region of 8110 is shown in SEQ ID NO:35, and the light chain variable region of 8110 is shown in SEQ ID NO:36.
[0307] The antibody can be an anti-C5 antibody or an antigen-binding fragment thereof comprising a heavy chain variable region amino acid sequence according to SEQ ID NO:37 and a light chain variable region amino acid sequence according to SEQ ID NO:38.
[0308] Example 5: Dual responder analysis of eculizumab versus placebo for both muscle strength and activities of daily living in patients with refractory generalized myasthenia gravis (gMG): Results from the REGAIN trial The objective of the examples was to evaluate the time course of response in patients who demonstrated a clinically significant response to eculizumab, as well as the proportion of patients who had a clinically significant relevant response to both MG-ADL and QMG. Patients with refractory gMG continued to receive a stable dose of IST (including corticosteroids) throughout the study; patients were randomly assigned to receive blinded eculizumab 900 mg weekly for 4 weeks, 1200 mg in the fifth week, and then 1200 mg every 2 weeks (n=62) or blinded placebo (n=63) (Figure 12).
[0309] Myasthenia Gravis Activities of Daily Living (MG-ADL) is a physician-prescribed, patient-reported measure of symptom severity related to MG-specific ADLs (Muppidi, Ann. NY Acad. Sci. 1274:114-19 (2012)), and the Quantitative Myasthenia Gravis (QMG) tool is a clinician-reported measure of muscle strength (Barohn et al., Ann. NY Acad. Sci. 841:769-72 (1998)). Prespecified responder analyses included the proportion of patients who responded with a ≥ 3-point improvement in MG-ADL total score without rescue; and the proportion of patients with a ≥ 5-point improvement in QMG total score without rescue. In ad hoc dual responder analyses, responders were defined as a ≥ 3-point improvement from baseline in MG-ADL total score and a ≥ 5-point improvement from baseline in QMG total score without rescue treatment. In addition to the prespecified responder thresholds (i.e., ≥3-point improvement for MG-ADL and ≥5-point improvement for QMG), thresholds of ≥4, 5, 6, 7, and 8 for MG-ADL and ≥6, 7, 8, 9, and 10 for QMG were also examined. P values from the Cochran-Mantel-Haenszel (CMH) test were provided for the more stringent criteria to aid interpretation.
[0310] More patients receiving eculizumab than those receiving placebo experienced clinically meaningful responses as defined above, and also experienced clinically meaningful relevant responses based on the more stringent thresholds for both MG-ADL and QMG total scores (Figure 13). MG-ADL responder analyses performed at each assessment date over the 26-week study are shown in Figure 14 (proportion of patients with a ≥ 3, 5, or 8 point change in MG-ADL). QMG responder analyses performed at each assessment date over the 26-week study are shown in Figure 15 (proportion of patients with a ≥ 5, 7, or 8 point change in QMG). is the proportion of patients with a change of >10 points). There was substantial overlap of patients who achieved a clinically significant response in both MG-ADL and QMG total scores (Figure 16). For each of the classification thresholds of response, there was a >3-fold increase in the proportion of improved patients in the eculizumab group compared with patients in the placebo group (Figure 16). More patients receiving eculizumab versus placebo achieved a clinically significant response at week 26 in both MG-ADL and QMG scores (week 26: eculizumab 40% vs placebo 13%; nominal P<0.001) (Figure 16). The benefit of eculizumab treatment was evident within the first 2 weeks (week 2: eculizumab 19% vs placebo 6% were dual responders; nominal P=0.0297) and was sustained through week 26 (all P≦0.05) (Figure 17).
[0311] Three times more patients with refractory gMG treated with eculizumab experienced clinically significant improvements in both muscle strength and ADLs compared with the placebo group by week 26. Increased rates of individual assessment responders (in both MG-ADLs and QMG) as well as dual responders emerged in the eculizumab-treated patient group compared with the placebo group, were observed early and were generally maintained over the course of the study.
[0312] As shown in Figure 18, the response rate was substantially higher in eculizumab-treated patients (40.3%) than in placebo-treated patients (12.7%), demonstrating clinically significant responses by both patient-assessed and physician-assessed outcome measures in eculizumab-treated patients. As response criteria became increasingly stringent, the superiority of response to eculizumab over placebo became more pronounced, with odds ratios exceeding 10.
[0313] Example 6: Eculizumab efficacy is maintained beyond 26 weeks in patients with AChR+ refractory generalized myasthenia gravis (gMG) Patients who completed REGAIN were allowed to continue into an open-label extension study known as ECU-MG-302. Each patient enrolled in the extension study underwent an initial 4-week blinded run-in before receiving open-label eculizumab maintenance treatment (1200 mg every 2 weeks). MG-ADL, QMG, MGC, and MG-QOL15 scores and safety were assessed.
[0314] In contrast to Study ECU-MG-301, where patients were required to maintain stable MG therapy over the 26-week study period, adjustments to background immunosuppressant therapy (IST), including corticosteroids and acetylcholinesterase inhibitors (AChIs), were permitted in Study ECU-MG-302. Investigators could change the dosing of existing IST / AChIs, discontinue existing IST / AChIs, or add new IST / AChIs.
[0315] MG-ADL total scores in eculizumab / eculizumab patients (n=56) did not change from open-label baseline to week 52. In placebo / eculizumab patients (n=60), rapid improvement in MG-ADL total scores from open-label baseline was demonstrated with change from ECU-MG-302 baseline in MG-ADL total scores observed as early as week 1 (-1.6 [-2.28, -0.89]; p<0.0001). The majority of the overall treatment effect was achieved by week 4 during the blinded run-in phase (-2.4 [-3.19, -1.71]; p<0.0001) and was maintained through week 52 (-2.7 [-3.73, -1.63]; p<0.0001). Changes in QMG, MGC, and MG-QOL15 total scores followed a pattern similar to that of MG-ADL (at week 52, QMG: -4.6; P < .0001; MGC: -5.1; P < .0001; and MG-QOL15: -5.7; P = .005). Similar response patterns were seen in the respiratory, bulbar, limb, and ocular MG-ADL domains. The safety profile of eculizumab remained unchanged throughout the open-label extension study and was consistent with the known profile. Ta.
[0316] Overall, 65 (55.6%) patients reported changes in their IST use during the study. A greater proportion of patients had a dose reduction or cessation of ≥1 IST than a dose increase or initiation of ≥1 IST (Table 26). Fifty-five (47.0%) patients decreased their daily dose of one IST, and two (1.7%) patients decreased their daily dose of >1 IST; 29 (24.8%) patients increased their daily dose of one IST, and no patients increased their dose of >1 IST. Nineteen (16.2%) patients stopped an existing IST; five (4.3%) patients started a new IST. The most common reason for ISR treatment was improvement of MG symptoms, with 42 (35.9%) patients reporting improvement of MG symptoms as the reason for changing IST treatment. In comparison, 21 (17.9%) patients reported worsening of MG symptoms as the primary reason for changing IST treatment. Side effects / intolerance to IST was reported as a reason for changing IST treatment in 13 (11.1%) patients.
[0317] [Table 29]
[0318] Overall, the extension studies demonstrated that patients who received eculizumab in Study ECU-MG-301 maintained their improvements through 52 weeks of additional eculizumab treatment in Study ECU-MG-302. For patients who received placebo in Study ECU-MG-301, improvements occurred rapidly after initiation of eculizumab treatment and were maintained through 52 weeks of Study ECU-MG-302, similar to the effects observed in eculizumab-treated patients in Study ECU-MG-301.
[0319] [Table 30]
[0320] [Table 31]
[0321] [Table 32]
[0322] [Table 33]
[0323] References: The following references are incorporated herein by reference in their entirety: (1) Conti-Fine et al., “Myasthenia gravis: past, present, and future”, J. Clin. Invest. 116(11):2843-54 (2006). (2) Howard JF, “Clinical Overview of MG,” Myasthenia Gravis Foundation of America, Inc. 2006. (3) Phillips, “The epidemiology of myasthenia gravis”, Semin. Neurol. 24(1):17-20 (2004). (4) Kim et al., “Treatment of myasthenia gravis based on its immunopathogenesis,” J. Clin. Neurol. 7(4):173-83 (2011). (5) Vincent et al., “Myasthenia gravis,” Adv. Neurol. 88:159-88 (2002). (6) Sahashi et al.、「Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J. Neuropathol. Exp. Neurol. 37(2):212-23 (1978). (7) Dalakas、「Intravenous immunoglobulin in autoimmune neuromuscular diseases,」JAMA 291(19):2367-75 (2004). (8) Engel et al.、「Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis:ultrastructural and light microscopic localization and electrophysiologic correlations,」 Mayo Clin. Proc. 52(5):267-80 (1977). (9) Nastuk et al.、「Changes in serum complement activity in patients with myasthenia gravis,」 Proc. Soc. Exp. Biol. Med. 105:177-84 (1960). (10) Peng et al.、「Role of C5 in the development of airway inflammation、airway hyperresponsiveness、and ongoing airway response,」 J. Clin. Invest. 115(6):1590-600 (2005). (11) Vakeva et al.、「Myocardial infarction and apoptosis after myocardial ischemia and reperfusion:role of the terminal complement components and inhibition by anti-C5 therapy,」 Circulation 97(22):2259-67 (1998). (12) Wang et al.、「Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model,」 Transplantation 68(11):1643-51 (1999). (13) Howard et al.、「A nandomized、double-blind、placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis,」 Muscle Nerve 48(1):76-84 (2013). (14) Muppidi et al.、「MG-ADL:still a relevant outcome measure,」 Muscle Nerve 44(5):727-31 (2011). (15) Benatar et al.、「Recommendations for myasthenia gravis clinical trials,」 Muscle Nerve 45(6):909-17 (2012). (16) Burns et al.、「The MG Composite:A valid and reliable outcome measure for myasthenia gravis,」 Neurology 74(18):1434-40 (2010). (17) Burns et al.、「The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis,」 Muscle Nerve 43(1):14-8 (2011). (18) Cella D.、Measuring Quality of Life in Neurological Disorders;Final Report of the Neuro- QOL Study September 2010. 2010. (19) Szende A. and Williams A.、「Measuring Self-Reported Population Health:An International Perspective based on EQ-5D、(2004) <http: / / www.euroqol.org / fileadmin / user_upload / Documenten / PDF / Books / Measuring_Self-Reported_Population_Health_-_An_International_Perspective_based_on_EQ-5D.pdf>. (20) Posner et al.、「The Columbia-Suicide Severity Rating Scale:initial validity and internal consistency findings from three multisite studies with adolescents and adults,」 Am. J. Psychiatry 168(12):1266-77 (2011). (21) Nilsson et al.、「Columbia-Suicide Se verity Rating Scale Scoring and Data Analysis Guide、(2013) <http: / / cssrs.columbia.edu / wp-content / uploads / ScoringandDataAnalysisGuide-for-Clinical-Trials.pdf>.
Claims
1. 1. A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of eculizumab; wherein the patient is positive for autoantibodies binding to nicotinic acetylcholine receptors (anti-AChR) and exhibits significant generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (1ST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability; and Patients will receive eculizumab for at least 26 weeks. The above method.
2. eculizumab is administered using a phased dosing schedule including an induction phase comprising administering a 900 mg induction dose of eculizumab on day 1, administering 900 mg doses of eculizumab on days 7, 14, and 21, and administering 1200 mg of eculizumab as a fifth induction dose on day 28; and 2. The method of claim 1, wherein the patient is administered eculizumab for at least 26 weeks.
3. 3. The method of claim 2, wherein the 28 day induction phase of eculizumab treatment is followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose, and administering 1200 mg of eculizumab every 14±2 days thereafter.
4. 4. The method of claim 3, further comprising performing plasmapheresis on the patient and administering eculizumab at a dose of between 300 mg and 1200 mg to the patient within 4 hours of completing the plasmapheresis.
5. 4. The method of claim 3, further comprising performing plasmapheresis on the patient and administering eculizumab at a dose of between 600 mg and 900 mg to the patient within 90 minutes of completing the plasmapheresis.
6. 4. The method of claim 3, further comprising performing plasmapheresis on the patient and administering eculizumab at a dose of 600 mg to the patient within 1 hour of completing the plasmapheresis.
7. 13. The method of claim 1, wherein the patient experiences a clinically meaningful improvement (reduction) in Myasthenia Gravis Activities of Daily Living (MG-ADL) score after 26 weeks of treatment.
8. 8. The method of claim 7, wherein the clinically meaningful improvement the patient experiences is at least a 3 point reduction in the patient's MG-ADL score after 26 weeks of treatment.
9. 10. The method of claim 1, wherein the patient experiences a clinically meaningful improvement (reduction) in Quantitative Myasthenia Gravis score (QMG) after 26 weeks of treatment.
10. 10. The method of claim 9, wherein the clinically meaningful improvement the patient experiences is at least a 4 point reduction in the patient's QMG score after 26 weeks of treatment.
11. 13. The method of claim 1, wherein the patient experiences a clinically meaningful improvement (reduction) in Myasthenia Gravis Composite (MGC) score after 26 weeks of treatment.
12. Patients experienced clinically meaningful improvements in their MGC scores after 26 weeks of treatment.
12. The method of claim 11, wherein the reduction is at least 6 points.
13. 10. The method of claim 1, wherein the patient experiences a clinically meaningful improvement (reduction) in quality of life as measured by Myasthenia Gravis Quality of Life (MG-QOL-15) score after 26 weeks of treatment.
14. 14. The method of claim 13, wherein the clinically meaningful improvement the patient experiences is at least a 6 point reduction in the patient's MG-QOL-15 score after 26 weeks of treatment.
15. 10. The method of claim 1, wherein the patient experiences a clinically meaningful improvement (reduction) in neuro-fatigue as measured by Neuro-QOL Fatigue score after 26 weeks of treatment.
16. 16. The method of claim 15, wherein the clinically meaningful improvement the patient experiences is at least an 8 point reduction in the patient's Neuro-QOL score after 26 weeks of treatment.
17. 10. The method of claim 1, wherein the patient experiences a clinically meaningful improvement (increase) in health status as measured by EQ-5D health status score after 26 weeks of treatment.
18. 1. A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient; wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR) and exhibits marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (1ST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability; Eculizumab is administered using a phased dosing schedule that includes an induction phase comprising a 900 mg induction dose of eculizumab administered on day 1, 900 mg doses of eculizumab administered on days 7, 14, and 21, and 1200 mg of eculizumab administered as a fifth induction dose on day 28; The patient has been administered eculizumab for at least 26 weeks; a 28-day induction phase of eculizumab treatment followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose, and administering 1200 mg of eculizumab every 14±2 days thereafter; and The patient has a clinically meaningful improvement (reduction) in at least two measures of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL; The above method.
19. 1. A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering eculizumab to the patient; wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR) and exhibits marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving treatment for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (1ST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability; eculizumab is administered using a phased dosing schedule including an induction phase comprising a 900 mg induction dose of eculizumab administered on day 1, 900 mg doses of eculizumab administered on days 7, 14, and 21, and 1200 mg of eculizumab administered as a fifth induction dose on day 28; The patient has been administered eculizumab for at least 26 weeks; a 28-day induction phase of eculizumab treatment followed by a maintenance phase comprising administering 1200 mg of eculizumab 14 days after the fifth induction dose, and administering 1200 mg of eculizumab every 14±2 days thereafter; and The patient has a clinically meaningful improvement (reduction) in five measures of generalized myasthenia gravis severity, where the five measures of generalized myasthenia gravis severity are a reduction of at least 3 points in MG-ADL, a reduction of at least 4 points in QMG, a reduction of at least 6 points in MGC, a reduction of at least 6 points in MG-QOL, and a reduction of at least 8 points in Neuro-QOL. The above method.
20. 20. The method of claim 19, wherein the patient has a clinically meaningful improvement (reduction) in five measures of generalized myasthenia gravis, wherein the five measures of generalized myasthenia gravis severity are at least a 4 point reduction in MG-ADL, at least a 5 point reduction in QMG, at least a 10 point reduction in MGC, at least an 11 point reduction in MG-QOL, and at least a 16 point reduction in Neuro-QOL.
21. 2. The method of claim 1, wherein eculizumab is administered by intravenous infusion.
22. 2. The method of claim 1, wherein eculizumab is administered subcutaneously.
23. 2. The method of claim 1, wherein the eculizumab comprises a heavy chain amino acid sequence according to SEQ ID NO: 10 and a light chain amino acid sequence according to SEQ ID NO:
11.
24. 2. The method of claim 1, wherein the eculizumab is an eculizumab variant comprising a heavy chain amino acid sequence according to SEQ ID NO: 14 and a light chain amino acid sequence according to SEQ ID NO:
11.
25. 13. The method of claim 1, wherein the patient has failed treatment with two or more 1STs in sequence or in combination for one or more years.
26. 13. The method of claim 1, wherein the patient has failed at least one 1ST and requires chronic plasma exchange or IVIg to control symptoms.
27. 2. The method of claim 1, wherein the therapeutically effective amount of eculizumab is maintained at a concentration of 50-100 μg / mL in the patient's serum.
28. 13. The method of claim 1, wherein the patient experiences a reduction in the administration of one or more 1STs after at least 26 weeks of treatment.
29. 13. The method of claim 1, wherein the patient experiences a reduction in 1ST dosing after at least 26 weeks of treatment.
30. 13. The method of claim 1, wherein the patient experiences a reduction in one or more 1ST dosing and cessation of one or more 1STs after at least 26 weeks of treatment.
Citation Information
Patent Citations
Anti-c5 antibodies having improved pharmacokinetics
WO2015134894A1
